
**PRECIPITATING FACTORS FOR HEPATIC
ENCEPHALOPATHY IN CIRRHOSIS OF LIVER-A ONE
YEAR CROSS SECTIONAL STUDY**

By

REG.NO:BG0114003

Dissertation

**Submitted to the
KLE University, Belagavi, Karnataka**

**In Partial Fulfillment
of the requirements for the degree of**

M. D.

in

GENERAL MEDICINE

**DEPARTMENT OF MEDICINE,
JAWAHARLAL NEHRU MEDICAL COLLEGE, BELAGAVI,
KARNATAKA**

APRIL-2017

KLE UNIVERSITY, BELAGAVI, KARNATAKA

ENDORSEMENT

This is to certify that the dissertation entitled **PRECIPITATING FACTORS FOR HEPATIC ENCEPHALOPATHY IN CIRRHOSIS OF LIVER-A ONE YEAR CROSS SECTIONAL STUDY** is a bonafide research work done by **REG NO. BG0114003**

Dr. REKHA S PATIL MD
Professor and Head,
Department of Medicine,
J. N. Medical College,
Nehru Nagar, Belagavi – 10

Date:
Place: Belagavi.

Dr. N. S. Mahantshetti MD
Principal,
J. N. Medical College,
Nehru Nagar, Belagavi – 10

Date:
Place: Belagavi.

| | | |
|------------------------------|---|--------------------------------|
| HE | : | Hepatic Encephalopathy |
| HRS | : | Hepatorenal syndrome |
| CL | : | Cirrhosis of Liver |
| WHC | : | West Haven Criteria |
| ALF | : | Acute Liver Failure |
| ACLF | : | Acute on Chronic Liver Failure |
| NH ₃ | : | Ammonia(unionised) |
| NH ₄ ⁺ | : | Ammonium ion |
| GLU | : | Glutamate |
| GLN | : | Glutamine |
| GNASE | : | Glutaminase |
| BBB | : | Blood-brain barrier |
| GABA | : | Gamma-amino-butyric acid |
| Ach | : | Acetylcholine |
| Ach E | : | Acetylcholine esterase |
| OHE | : | Overt Hepatic Encephelopathy |
| GCS | : | Glasgow Coma Scale |
| CHE | : | Covert Hepatic Encephelopathy |

| | | |
|-------|---|---|
| MHE | : | Minimal Hepatic Encephelopathy |
| PSE | : | Portosystemic Encephelopathy |
| PHES | : | Psychometric Hepatic Encephalopathy Score |
| CFE | : | Critical Flicker Frequency |
| CRT | : | Continuous Reaction Time |
| ICT | : | Inhibitory Control Test |
| BCAAs | : | branched-chain amino acids |
| LOLA | : | L-ornithine Laspartate |
| GPB | : | Glyceryl phenylbutyrate |

ABSTRACT

Purpose: Hepatic encephalopathy(HE) describes a spectrum of potentially reversible neuropsychiatric abnormalities in patients of cirrhosis of liver. HE is a well recognised clinical complication of cirrhosis of liver and the prompt identification of well defined precipitating factors is extremely important in diagnosis and treatment of this fatal condition

Objectives: To study precipitating factors for hepatic encephalopathy in cirrhosis of liver.

Methodology: A cross sectional study was conducted in patients presenting to Department of Internal medicine at KLES Dr Prabhakar Kore Hospital & MRC, Belgaum fulfilling inclusion criteria, for hepatic encephalopathy with cirrhosis of liver and subjected to detailed history, examination and processed through necessary investigations with informed consent

Results: In this study infection (SBP + other infections) 41.66%(35) is the commonest precipitating factor for HE, followed by electrolyte imbalance 34.52(29), upper GI bleeding with 32.14%(27) of patients and constipation 4.76%(4). Among the infections spontaneous bacterial peritonitis 21.43%(18) is the commonest precipitating factor followed by other infections 20.41%(17) like cellulitis of extremities and abdominal wall 9.52%(8) , 5.95%(5) cases are pneumonia, 2 are of acute gastroenteritis and other 2 are undiagnosed but presented with fever and raised leucocyte count.

In electrolyte imbalance hyponatremia 16.67%(14) is the most commonest electrolyte disturbance causing HE. In our study hypomagnesaemia 8.33%(7 cases) is seen as precipitating factor for HE.

Among the participants (N=84) Grade I HE is seen in only 2 cases, 58.33%(49 patients have grade II hepatic encephelopathy, 34.52%(29) have grade III HE, 4.76%(4) have grade IV HE.

Grade I HE showing equal association with single and multiple precipitating factors, Grade II HE, 43 (83.67%) were having single precipitating factor. 65.5% of patients of Grade III HE had single precipitating factor. All Grade IV, were associated with single precipitating factor. There is no correlation of Grade of HE to number of precipitating factors.

Among 2 patients of Grade I, one was having infection. Among 49 patients of Grade II 23(46.94%) were having infection. Among 29 patients of Grade III 10(34.48%) were having infection. Among 4 patients of Grade IV only 1 patient was having infection. In 84 patients of HE, 35(41.67%) were precipitated by infection, in which Grade II was common.

In our study 27 patients had upper GI bleed. 19 patients (out of 27) had Grade III HE. 29 patients had electrolyte imbalance. 21 patients (out of 29) had Grade II HE.

In our study 57.14%(48) patients had Child Pugh class B and 42.86%(36) had Child Pugh class C. As grade of HE increases so does child Pugh score and child Pugh class is directly proportional to grade of HE.

Conclusion: Infection is the commonest risk factor for hepatic encephalopathy, followed by electrolyte imbalance, upper GI bleeding, HRS, and constipation.

Grade II HE is the most common presentation seen in this study. There is no correlation of Grade of HE to number of precipitating factors. There is no correlation of Grade of HE to infection. Upper GI bleeding patients had presented mostly with Grade III HE. Electrolyte imbalance had presented mostly with Grade II HE.

In our study we observed that hypomagnesemia is a precipitating factor for HE. Role of magnesium in causing HE in patients of CL is important as correction of it shows a dramatic response. So monitoring of serum magnesium level is important in a patient with HE. As sample size of present study is small larger studies are required to confirm the role of magnesium as a precipitating factor for HE in cirrhosis of liver patients.

Limitations:

- Sample size was small to generalize the study result.
- This study was done in a short period, so all factors in relation to precipitating factors for HE in CL cannot be studied.
- Study was conducted only in single centre . So this study result would not be generalized for the entire country.

CONTENTS

| SL. NO. | TOPIC | PAGE NO. |
|----------------|------------------------------------|-----------------|
| 1. | INTRODUCTION | |
| 2. | OBJECTIVES | |
| 3. | REVIEW OF LITERATURE | |
| 4. | METHODOLOGY | |
| 5. | RESULTS | |
| 6. | DISCUSSION | |
| 7. | CONCLUSION | |
| 8. | SUMMARY | |
| 9. | BIBLIOGRAPHY | |
| 10. | ANNEXURES | |
| | ANNEXURE I – CONSENT FORM | |
| | ANNEXURE II – PROFORMA | |
| | ANNEXURE III – MASTER CHART | |

LIST OF TABLES

| SL NO | TABLE | PAGE NO. |
|----------|---|-------------|
| 1 | AGE WISE DISTRIBUTION | |
| 2 | DISTRIBUTION OF PATIENTS BY GENDER | |
| 3 | DISTRIBUTION OF PATIENTS BY GENDER | |
| 4 | PRECIPITATING FACTORS FOR HEPATIC ENCEPHALOPATHY IN ORDER OF FREQUENCY | |
| 5 | SPONTANEOUS BACTERIAL PERITONITIS AS A PRECIPITATING FACTOR | |
| 6 | HE CAUSED BY OTHER INFECTIONS | |
| 7 | UPPER GI BLEEDING AS A PRECIPITATING FACTOR | |
| 8 | HYPONATRAEMIA AS A PRECIPITATING FACTOR | |
| 9 | HEPATORENAL SYNDROME AS A PRECIPITATING FACTOR | |
| 10 | HYPERKALAEMIA AS A PRECIPITATING FACTOR | |
| 11 | HYPOMAGNESEMIA AS A PRECIPITATING FACTOR | |

| | | |
|----|---|--|
| 12 | CONSTIPATION AS A PRECIPITATING FACTOR | |
| 13 | HE GRADES WISE DISTRIBUTION | |
| 14 | ASSOCIATION BETWEEN SINGLE AND MULTI PRECIPITATING FACTORS WITH HE GRADE | |
| 15 | ASSOCIATION BETWEEN INFECTION (SPONTANEOUS BACTERIAL PERITONITIS + OTHER INFECTIONS) WITH HE GRADES | |
| 16 | UPPER GI BLEEDING TO GRADE OF HE | |
| 17 | ELECTROLYTE IMBALANCE TO HE GRADE | |
| 18 | CHILD PUGH SCORE WITH GRADE OF HEPATIC ENCEPHELOPATHY | |
| 19 | ASSOCIATION BETWEEN INFECTION (SPONTANEOUS BACTERIAL PERITONITIS + OTHER INFECTIONS) WITH OTHER CAUSES OF HEPATIC ENCEPHELOPATHY | |

LIST OF GRAPHS

| SL NO | GRAPH | PAGE NO. |
|--------------|--|-----------------|
| 1 | DISTRIBUTION OF PATIENTS BY AGE GROUPS | |
| 2 | DISTRIBUTION OF PATIENTS BY EDUCATION | |
| 3 | SPONTANEOUS BACTERIAL PERITONITIS AS A PRECIPITATING FACTOR | |
| 4 | HE CAUSED BY OTHER INFECTIONS | |
| 5 | UPPER GI BLEEDING AS A PRECIPITATING FACTOR | |
| 6 | HYPONATRAEMIA AS A PRECIPITATING FACTOR | |
| 7 | HEPATORENAL SYNDROME AS A PRECIPITATING FACTOR | |
| 8 | HYPERKALAEMIA AS A PRECIPITATING FACTOR | |
| 9 | HYPOMAGNESEMIA AS A PRECIPITATING FACTOR | |
| 10 | CONSTIPATION AS A PRECIPITATING FACTOR | |
| 11 | HE GRADES WISE DISTRIBUTION | |
| 12 | ASSOCIATION BETWEEN SINGLE AND MULTI PRECIPITATING FACTORS WITH HE GRADE | |
| 13 | ASSOCIATION BETWEEN INFECTION (SPONTANEOUS BACTERIAL PERITONITIS + OTHER INFECTIONS) WITH | |

| | | |
|-----------|---|--|
| | HE GRADES | |
| 14 | ASSOCIATION BETWEEN INFECTION (SPONTANEOUS BACTERIAL PERITONITIS + OTHER INFECTIONS) WITH OTHER CAUSES OF HEPATIC ENCEPHELOPATHY | |

LIST OF FIGURES

| SL NO | FIGURE | PAGE NO. |
|--------------|--|---------------------|
| 1 | INTERORGAN AMMONIA TRAFFICKING AND METABOLISM | |
| 2 | HYPOTHESIS OF MULTI-FACTORIAL NATURE OF HE | |

INTRODUCTION

Hepatic encephelopathy(HE) is a syndrome observed in patients with cirrhosis of liver. Hepatic encephalopathy is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, after exclusion of brain disease¹.Hepatic encephalopathy (HE) is present in upto 70% of all patients with cirrhosis, including patients with abnormalities demonstrable only by psychometric testing². It accompanies portal-systemic shunting of venous blood that occurs either spontaneously, due to portal hypertension, or surgically following porto-caval anastomosis surgery or trans-jugular intra-hepatic porto-systemic stent shunt (TIPS) aimed at relieving portal hypertension. About 30% of patients with cirrhosis of liver die due to hepatic coma. A precipitating factor can be usually identified for acute HE in cirrhosis of liver patient and the treatment of the episode is directed towards the correction of this precipitant. Once the precipitating condition has been resolved, the encephalopathy also subsides usually.³ Hepatic Encephalopathy could be acute, sub acute, or chronic or it may be clinical or subclinical.

Historically, the role of ammonia accumulation has dominated explanations of the pathogenesis of HE. However over the past decade evidence has emerged for a role of other concurrent factors (such as inflammation, hyponatraemia) in the development of HE. HE is a well

recognized clinical complication of cirrhosis of liver and the presence and prompt identification of well defined precipitating factors is extremely important in diagnosis and treatment of this fatal condition. About 30% of patients with cirrhosis of liver die due to hepatic coma.⁴

Five years after the diagnosis of cirrhosis, there is 26% probability for developing at least one episode of HE⁵. HE is also a common problem after insertion of a transjugular intrahepatic portosystemic shunt (TIPS)^{6,7}. Despite the impressive advances in our understanding of the several pathophysiological mechanisms which are involved in HE, the treatment options remain an unmet clinical need, accompanied by considerably high mortality rates. After the first clinical manifestation of HE, the patients' prognosis is very poor; probability of five-year survival is 16% to 22%, compared with that of 55% to 70% in cirrhotic patients without HE^{5,8}. The pathophysiology of chronic HE is apparently multifactorial, with several circulating neurotoxins being involved. The systemic accumulation of ammonia neurotoxic concentrations seems to be the most prominent factor^{9,10}, while the inter organ ammonia and amino acid metabolism is of pivotal importance in the pathogenesis of HE. Since Nencki and Pavlov described meat intoxicification in portacaval shunted dogs over 100 years ago¹¹ ammonia has been considered as a central factor to the pathogenesis of HE¹² The

clinical importance of hyperammonemia's role in patients with liver failure is no more evident than in the observation that ammonia levels of $>150 \mu\text{mol/L}$ predict brain herniation, coma and death in patients with ALF¹³. Several treatment agents such as lactitol, lactulose, L-ornithine-L-aspartate and rifaximin aim to lower blood and cerebral ammonia levels and thereby attenuate its toxic effects.

1.2 Research Question

What are the precipitating factors for hepatic encephalopathy in alcoholic cirrhosis of liver?

Frequency of precipitating factors in hepatic encephalopathy in ethanol related cirrhosis of liver?

1.3 Objectives

1.3.1 General objective

To explore the common precipitating factors for hepatic encephalopathy in cirrhosis of liver

1.3.2 Specific objectives

To determine the weather calcium and magnesium can cause HE in cirrhosis of liver, and frequency of other precipitating factors.

1.4 Operational definition

HEPATIC ENCEPHELOPATHY

HE refers to a complex and potentially reversible or progressive syndrome of cerebral dysfunction, which consists of neuropsychiatric, cognitive and motor components, characterized by a broad etiological spectrum. It is observed in cirrhotic patients and those with acute liver failure (ALF) in the absence of other known brain disease, as a result of decompensated liver function.¹

OBJECTIVES

1. To study precipitating factors for hepatic encephalopathy in cirrhosis of liver.

REVIEW OF LITERATURE

Hepatic encephalopathy (HE) is a frequent complication and one of the most debilitating manifestations of liver disease, severely affecting the lives of patients and their caregivers. Furthermore, cognitive impairment associated with cirrhosis results in utilization of more health care resources in adults than other manifestations of liver disease.¹⁴ Progress in the area has been hindered by the complex pathogenesis that is not yet fully elucidated. Apart from such biological factors, there remains the larger obstacle that there are no universally accepted standards for the definition, diagnosis, classification, or treatment of HE, mostly as a result of insufficient clinical studies and standardized definitions.

DEFINITION OF THE DISEASE/CONDITION

OVERVIEW

Advanced liver disease and portosystemic shunting (PSS), far from being an isolated disorder of the liver, have well-known consequences on the body and, notably, on brain functioning. The alterations of brain functioning, which can produce behavioral, cognitive, and motor effects, were termed portosystemic encephalopathy (PSE)¹⁵ and later included in the term HE.¹⁶ Unless the underlying liver disease is successfully treated, HE is associated with poor survival and a high risk of recurrence.^{17,18} Even in its mildest form, HE reduces health-related quality of life and is a risk factor for bouts of severe HE.¹⁹⁻²¹

DEFINITION OF HE

Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or PSS; it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. This definition, in line with previous versions,^{22,23} is based on the concept that encephalopathies are “diffuse

disturbances of brain function”¹⁷ and that the adjective “hepatic” implies a causal connection to liver insufficiency and/or perihepatic vascular shunting.¹⁸

EPIDEMIOLOGY

The incidence and prevalence of HE are related to the severity of the underlying liver insufficiency and PSS.²⁴⁻²⁷ In patients with cirrhosis, fully symptomatic overt HE (OHE) is an event that defines the decompensated phase of the disease, such as VB or ascites.¹⁹ Overt hepatic encephalopathy is also reported in subjects without cirrhosis with extensive PSS.^{20,21} The manifestation of HE may not be an obvious clinical finding and there are multiple tools used for its detection, which influences the variation in the reported incidence and prevalence rates. The prevalence of OHE at the time of diagnosis of cirrhosis is 10%-14% in general,²⁸⁻³⁰ 16%-21% in those with decompensated cirrhosis,^{19, 31} and 10%-50% in patients with transjugular intrahepatic portosystemic shunt (TIPS).^{32,33} The cumulated numbers indicate that OHE will occur in 30%-40% of those with cirrhosis at some time during their clinical course and in the survivors in most cases repeatedly.³⁴ Minimal HE (MHE) or covert HE (CHE) occurs in 20%-80% of patients with cirrhosis.³⁵⁻³⁹ The prevalence of HE in prehepatic noncirrhotic portal hypertension (PH) is not well defined. The risk for the first bout of OHE is 5%-25% within 5 years after cirrhosis diagnosis, depending on the presence of risk factors, such as other complications to cirrhosis (MHE or CHE, infections, VB, or ascites) and probably diabetes and hepatitis C. Subjects with a previous bout of OHE were found to have a 40% cumulative risk of recurring OHE at 1 year,⁴⁰ and subjects with recurrent OHE have a 40% cumulative risk of another recurrence within 6 months, despite lactulose treatment. Even individuals with cirrhosis and only mild cognitive dysfunction or mild electroencephalography (EEG) slowing develop approximately one bout of OHE

per 3 years of survival.^{41,42} After TIPS, the median cumulative 1-year incidence of OHE is 10%-50%^{43,44} and is greatly influenced by the patient selection criteria adopted.⁴⁵ Comparable data were obtained by PSS surgery. It gives an idea of the frequent confrontation of the health care system by patients with HE that they accounted for approximately 110,000 hospitalizations yearly (2005-2009)⁴⁶ in the United States. Though numbers in the European Union (EU) are not readily available, these predictions are expected to be similar. Furthermore, the burden of CLD and cirrhosis is rapidly increasing,^{47,48} and more cases will likely be encountered to further define the epidemiology of HE.

CLINICAL PRESENTATION

Hepatic encephalopathy produces a wide spectrum of nonspecific neurological and psychiatric manifestations.²² In its lowest expression, HE alters only psychometric tests oriented toward attention, working memory (WM), psychomotor speed, and visuospatial ability, as well as electrophysiological and other functional brain measures.⁴⁹ As HE progresses, personality changes, such as apathy, irritability, and disinhibition, may be reported by the patient's relatives, and obvious alterations in consciousness and motor function occur. Disturbances of the sleepwake cycle with excessive daytime sleepiness are frequent,⁵⁰ whereas complete reversal of the sleepwake cycle is less consistently observed. Patients may develop progressive disorientation to time and space, inappropriate behavior, and acute confusional state with agitation or somnolence, stupor, and, finally, coma.⁵¹ The recent ISHEN (International Society for Hepatic Encephalopathy and Nitrogen Metabolism) consensus uses the onset of disorientation or asterixis as the onset of OHE. In non-comatose patients with HE, motor system abnormalities, such as hypertonia, hyper-

reflexia, and a positive Babinski sign, can be observed. In contrast, deep tendon reflexes may diminish and even disappear in coma, although pyramidal signs can still be observed. Rarely, transient focal neurological deficits can occur.⁵² Seizures are very rarely reported in HE.⁵³⁻⁵⁵ Extrapyrarnidal dysfunction, such as hypomimia, muscular rigidity, bradykinesia, hypokinesia, monotony and slowness of speech, parkinsonian-like tremor, and dyskinesia with diminished voluntary movements, are common findings; in contrast, the presence of involuntary movements similar to tics or chorea occur rarely.⁵⁶ Asterixis or “flapping tremor” is often present in the early to middle stages of HE that precede stupor or coma and is, in actuality, not a tremor, but a negative myoclonus consisting of loss of postural tone. It is easily elicited by actions that require postural tone, such as hyperextension of the wrists with separated fingers or the rhythmic squeezing of the examiner’s fingers. However, asterixis can be observed in other areas, such as the feet, legs, arms, tongue, and eyelids. Asterixis is not pathognomonic of HE because it can be observed in other diseases⁵⁶ (e.g., uremia). Notably, the mental (either cognitive or behavioral) and motor signs of HE may not be expressed, or do not progress in parallel, in each individual, therefore producing difficulties in staging the severity of HE. Hepatic myelopathy (HM) is a particular pattern of HE possibly related to marked, long-standing portocaval shunting, characterized by severe motor abnormalities exceeding the mental dysfunction. Cases of paraplegia with progressive spasticity and weakness of lower limbs with hyper-reflexia and relatively mild persistent or recurrent mental alterations have been reported and do not respond to standard therapy, including ammonia lowering, but may reverse with liver transplantation (LT).⁵⁷ Persistent HE may present with prominent extrapyramidal and/or pyramidal signs, partially overlapping with HM, in which postmortem brain examination reveals brain atrophy. This

condition was previously called acquired hepatolenticular degeneration, a term currently considered obsolete. However, this cirrhosis-associated parkinsonism is unresponsive to ammonia-lowering therapy and may be more common than originally thought in patients with advanced liver disease, presenting in approximately 4% of cases.

Apart from these less-usual manifestations of HE, it is widely accepted in clinical practice that all forms of HE and their manifestations are completely reversible, and this assumption still is a well-founded operational basis for treatment strategies.

CLASSIFICATION

Hepatic encephalopathy should be classified according to all of the following four factors.¹⁰

1. According to the underlying disease, HE is subdivided into

- Type A resulting from ALF
- Type B resulting predominantly from portosystemic bypass or shunting
- Type C resulting from cirrhosis

The clinical manifestations of types B and C are similar, whereas type A has distinct features and, notably, may be associated with increased intracranial pressure and a risk of cerebral herniation.

2. **According to the severity of manifestations.** The continuum that is HE has been arbitrarily subdivided. For clinical and research purposes, a scheme of such grading is provided.

| WHC INCLUDING MHE | ISHEN | DESCRIPTION | SUGGESTED OPERATIVE CRITERIA | COMMENT |
|-------------------|--------|---|--|---|
| Unimpaired | | No encephalopathy at all, no history of HE | Tested and proved to be normal | |
| Minimal | covert | Psychometric or neuropsychological alterations of tests exploring psychomotor speed/executive functions or neurophysiological alterations without clinical evidence of mental change | Abnormal results of established psychometric or neuropsychological tests without clinical manifestations | No universal criteria for diagnosis Local standards and expertise required |
| Grade I | | <ul style="list-style-type: none"> • Trivial lack of awareness • Euphoria or anxiety • Shortened attention span • Impairment of addition or subtraction • Altered sleep rhythm | Despite oriented in time and space (see below), the patient appears to have some cognitive/behavioral decay with respect to his or her standard on clinical examination or to the caregivers | Clinical findings usually not reproducible |

| | | | | |
|-----------|-------|---|---|---|
| Grade II | overt | Lethargy or apathy <ul style="list-style-type: none"> • Disorientation for time • Obvious personality change • Inappropriate behavior • Dyspraxia • Asterixis | Disoriented for time (at least three of the followings are wrong: day of the month, day of the week, month, season, or year) ± the other mentioned symptoms | Clinical findings variable, but reproducible to some extent |
| Grade III | | Somnolence to semistupor • Responsive to stimuli • Confused <ul style="list-style-type: none"> • Gross disorientation • Bizarre behavior | Disoriented also for space (at least three of the following wrongly reported: country, state [or region], city, or place) ± the other mentioned symptoms | Clinical findings reproducible to some extent |
| Grade IV | | Coma | Does not respond even to painful stimuli | Comatose state usually reproducible |

Operative classifications that refer to defined functional impairments aim at increasing intra- and inter-rater reliability and should be used whenever possible.

3. **According to its time course**, HE is subdivided into

- Episodic HE
- Recurrent HE denotes bouts of HE that occur with a time interval of 6 months or less.
- Persistent HE denotes a pattern of behavioral alterations that are always present and interspersed with relapses of overt HE.

4. **According to the existence of precipitating factors**, HE is subdivided into

- Nonprecipitated
- Precipitated, and the precipitating factors should be specified.

Precipitating factors can be identified in nearly all bouts of episodic HE type C and should be actively sought and treated when found.

PRECIPITATING FACTORS FOR OHE BY DECREASING FREQUENCY

| EPISODIC | RECURRENT |
|-----------------------|----------------------|
| Infections | Electrolyte disorder |
| GI bleeding | Infection |
| Diuretic overdose | Unidentified |
| Electrolyte imbalance | Constipation |
| Constipation | Diuretic Overdose |
| Unidentified | GI bleeding |

5. A fifth classification, according to whether or not the patient has acute-on-chronic liver failure (ACLF), has recently been suggested.⁵⁹ Although the management, mechanism, and prognostic impact differ, this classification is still a research area.

PATHOGENESIS

The two elements that confer the name to the syndrome and intervene in its clinical classification are neurological disturbance and liver failure. According to the characteristics of the neurological manifestations, HE is classified as episodic (previously acute), persistent (previously chronic), or minimal (previously subclinical).⁶⁰ Depending on the disease of the liver, HE is termed type C (associated with cirrhosis), type A (associated with acute liver failure), or type B (associated with portal-systemic bypass and no intrinsic liver disease). Irrespective of the characteristics of the neurological manifestations and the type of liver disease, the link between them is that HE is caused by the effects on the brain of substances that under normal circumstances are efficiently metabolized by the liver. Ammonia remains as the most important factor in the pathogenesis of HE. Currently, there is a better explanation of the mechanisms by which ammonia interferes with brain function and a better recognition of the factors that influence these effects.

Ammonia

The association between ammonia neurotoxicity and HE was first suggested by studies in dogs that underwent portal-cava anastomosis (Eck's fistula) and developed neurological manifestations when fed meat.⁶¹ Ammonia is generated in the intestines from different sources: nitrogenous components of the diet, deamination of glutamine, and breakdown of urea by urease present in colonic flora. These features have been known for many years and have been the basis for designing treatments for HE based on the modulation of intestinal generation of ammonia (Fig. 1). Glutaminase, the enzyme that metabolizes the deamination of glutamine, has been thought to play an important role in the pathogenesis of HE.⁶² In the intestines, the activity of glutaminase has been associated with minimal HE, probably because it

regulates the generation of ammonia.⁶³ Neomycin, a drug that improves HE, may act by inhibiting intestinal glutaminase. In the brain, glutaminase is located in the mitochondria of astrocytes and might be implicated in the toxic effects of ammonia in this organelle.⁶⁴ Interorgan ammonia trafficking has been quantified in cirrhotic patients.⁶⁵ The relative contribution of different organs highlights the role of skeletal muscle to buffer ammonia that is produced in the intestines and is not metabolized in the liver. These data suggest that favoring an anabolic metabolic state may decrease ammonia concentration in the blood. A negative protein balance has been shown in advanced cirrhosis. This balance can be partially reversed in different clinical situations. Isoleucine infusions promote protein synthesis after gastrointestinal bleeding,⁶⁶ anabolic steroids improve nutritional status in moderately malnourished patients with acute alcoholic hepatitis, and a diet with normal protein content avoids the increased protein breakdown seen in patients with episodic HE treated with low-protein diets.⁶⁷ Malnourishment, which traditionally has been linked to a worse clinical outcome in cirrhosis, may be difficult to combat through diet interventions. Branched chain amino acids may be helpful for this purpose, because they promote protein synthesis.⁶⁸ The administration of branched chain amino acids-enriched diets may slow the progression of cirrhosis⁶⁹ and through this mechanism improve persistent HE. The kidney is another organ that is important in regulating blood ammonia levels. An increase in the generation of ammonia in the kidney has been shown after gastrointestinal bleeding⁷⁰ and may follow dehydration and the administration of diuretics. Expansion of plasma volume, a common practice in patients with episodic HE, increases the excretion of urea in the urine and may be helpful to shorten the duration of HE.⁷¹ A common criticism of the role of ammonia in HE has been the lack of a good correlation between blood levels and the severity of

HE.⁷² At physiological pH, blood ammonia is mostly ionized (NH₄). Small changes in pH have effects in the equilibrium and affect the amount of un-ionized ammonia (NH₃), which is the form that passes the blood-brain barrier by diffusion. In some studies, the correlation between arterial ammonia and HE has been improved after adjusting for pH,⁷³ but this has not been confirmed by other authors.⁷⁴ Part of the lack of association between plasma ammonia and HE can be accounted for by differences in ammonia concentration between blood and the central nervous system. This difference could be explained by differences in pH between the compartments and by the presence of active transporters. It has been estimated that at least 20% of ammonia may pass the blood-brain barrier ionized (NH₄) through an active transport.⁷⁵ Cerebral blood flow and the permeability surface area are other elements that may determine the delivery of ammonia to the brain.

Inflammation

Apart from ammonia, there are other factors that appear to have an important role in the development of HE. This is apparent from the differences between HE in cirrhosis and other diseases that share high levels of ammonia but different clinical outcomes, such as inborn errors of metabolism or congenital portal-systemic shunts.⁷⁶

In the latter, magnetic resonance studies and oral glutamine challenge tests have reproduced the same abnormalities as those present in cirrhosis.⁷⁷ However, episodic HE is very infrequent in patients with congenital shunts. One factor that may explain the development of episodic HE in cirrhosis is inflammation.⁷⁸ The presence of markers of a systemic inflammatory response has been linked to HE.⁷⁹ In patients with acute liver failure, it is well documented that the progression to severe HE is

associated with infection.⁸⁰ The exposition of astrocytes to cytokines in cultures induces astrocyte swelling, which is considered a neuropathological hallmark of HE.⁸¹ In experimental models, lipopolysaccharide enhances ammonia-induced changes in cerebral hemodynamics.⁸² For these reasons, it has been postulated that the inflammatory response may unlock the blood-brain barrier to the effects of toxins and may be responsible for most of the bouts of overt HE.⁸³ Interestingly, subclinical infection has been demonstrated among patients with advanced cirrhosis.⁸⁴ The induction of inflammatory response by these infections may cause those episodes of HE in which a precipitating event cannot be identified.




Figure 1: Interorgan ammonia trafficking and metabolism. Ammonia is generated in the intestines from nitrogenous compounds from the diet, deamination of glutamine by glutaminase, and metabolism of nitrogenous substances by colonic flora. In normal circumstances, most ammonia is metabolized to urea in the liver. Portal-systemic

shunts and liver failure cause a rise in blood ammonia that may affect brain function by inducing several disturbances in astrocytes; these may impair mitochondria and the glutamate-glutamine trafficking between neurons and astrocytes. Skeletal muscle is capable of decreasing blood ammonia by metabolizing ammonia to glutamine. The kidney has also an important role in determining blood ammonia by excreting urea in the urine and generating ammonia. NH₃, ammonia; GLU, glutamate; GLN, glutamine; GNASE, glutaminase; BBB, blood-brain barrier.

Brain Disturbances

New technological advances have allowed a better knowledge of the disturbances present in the brain in HE, not only in experimental models, but also in patients with cirrhosis. Results of neuropathologic, spectroscopic, and neurochemical studies continue to indicate a major role for ammonia.⁸⁵ Although there is no unifying hypothesis, the molecular mechanisms of ammonia toxicity point at two important steps: (1) abnormalities in the metabolism of neurotransmitters and (2) neurotoxicity induced by oxidative stress. Glutamate is an amino acid that acts as an excitatory neurotransmitter and is present in presynaptic vesicles in more than 90% of the neurons. After its release and activation of different postsynaptic receptors, glutamate is removed from the synaptic cleft by transporters located at the astrocytes. In the astrocytes, glutamate is transformed into glutamine with the incorporation of one molecule of ammonia and transported into the presynaptic neuron, where glutamine will be transformed again into glutamate. This cycle is affected at several steps by ammonia, which has led to the proposal that impaired glutamatergic neurotransmission induces part of the neurological manifestations of HE. However, experimental attempts to modify these abnormalities have shown only marginal

amelioration. Another neurotransmitter system that is affected by ammonia is the inhibitory GABAergic neurotransmission. One of the mechanisms involved is the activation of neurosteroids, which are agonists of the γ -aminobutyric acid (GABA) receptor and may be responsible for the inhibitory pattern of neuronal function that characterizes HE.⁸⁶ Ammonia has been shown to evoke oxidative stress inducing the generation of free radicals and the nitrotyrosination of proteins in the brain.⁸⁷ This process is critical for mitochondrial function and secondarily may cause failure of normal neurotransmission. Signs of impending energy failure have been shown in experimental models⁸⁸ and in patients with acute liver failure. Figure 1 Interorgan ammonia trafficking and metabolism. Ammonia is generated in the intestines from nitrogenous compounds from the diet, deamination of glutamine by glutaminase, and metabolism of nitrogenous substances by colonic flora. In normal circumstances, most ammonia is metabolized to urea in the liver. Portal-systemic shunts and liver failure cause a rise in blood ammonia that may affect brain function by inducing several disturbances in astrocytes; these may impair mitochondria and the glutamate-glutamine trafficking between neurons and astrocytes. Skeletal muscle is capable of decreasing blood ammonia by metabolizing ammonia to glutamine. The kidney has also an important role in determining blood ammonia by excreting urea in the urine and generating ammonia. An additional effect of oxidative and nitrosative stress in astrocytes is the induction of swelling,⁸⁹ which has been consistently reproduced after exposure to ammonia. Astrocyte swelling can be exacerbated by some of the factors that precipitate HE, such as inflammatory mediators, hyponatremia, and benzodiazepines.⁹⁰ The change in the state of cellular hydration causes impairment of several metabolic pathways and has been suggested as being responsible for brain edema and for the neurological manifestations of HE.⁹¹




Figure 2 : Hypothesis of multi-factorial nature of HE

Differential Diagnosis of HE

The diagnosis requires the detection of signs suggestive of HE in a patient with severe liver insufficiency and/or PSS who does not have obvious alternative causes of brain dysfunction. The recognition of precipitating factors for HE (e.g., infection, bleeding, and constipation) supports the diagnosis of HE. The differential diagnosis should consider common disorders altering the level of consciousness

Overt HE or acute confusional state

Diabetic (hypoglycemia, ketoacidosis, hyperosmolar, lactate acidosis) Alcohol (intoxication, withdrawal, Wernicke) Drugs (benzodiazepines, neuroleptics, opioids) Neuroinfections Electrolyte disorders (hyponatremia and hypercalcemia) Nonconvulsive epilepsy Psychiatric disorders Intracranial bleeding and stroke Severe medical stress (organ failure and inflammation)

Other presentations

Dementia (primary and secondary) Brain lesions (traumatic, neoplasms, normal pressure hydrocephalus) Obstructive sleep apnea Hyponatremia and sepsis can both produce encephalopathy per se and precipitate HE by interactions with the pathophysiological mechanisms. In endstage liver disease, uremic encephalopathy and HE may overlap.

management

1. Hepatic encephalopathy should be classified according to the type of underlying disease, severity of manifestations, time course, and precipitating factors (GRADE III, A, 1).
2. A diagnostic workup is required, considering other disorders that can alter brain function and mimic HE (GRADE II-2, A, 1).

Diagnosis and Testing

Clinical Evaluation

Judging and measuring the severity of HE is approached as a continuum.⁹² The testing strategies in place range from simple clinical scales to sophisticated psychometric and neurophysiological tools; however, none of the current tests are valid for the entire spectrum.⁹³ The appropriate testing and diagnostic options differ according to the acuity of the presentation and the degree of impairment.⁹⁴

Diagnosis and Testing for OHE

The diagnosis of OHE is based on a clinical examination and a clinical decision. Clinical scales are used to analyze its severity. Specific quantitative tests are only needed in study settings. The gold standard is the West Haven criteria (WHC; including clinical description). However, they are subjective tools with limited

interobserver reliability, especially for grade I HE, because slight hypokinesia, psychomotor slowing, and a lack of attention can easily be overlooked in clinical examination. In contrast, the detection of disorientation and asterixis has good interrater reliability and thus are chosen as marker symptoms of OHE.⁹⁴ Orientation or mixed scales have been used to distinguish the severity of HE.^{95,96} In patients with significantly altered consciousness, the Glasgow Coma Scale (GCS) is widely employed and supplies an operative, robust description. Diagnosing cognitive dysfunction is not difficult. It can be established from clinical observation as well as neuropsychological or neurophysiological tests. The difficulty is to assign them to HE. For this reason, OHE still remains a diagnosis of exclusion in this patient population that is often susceptible to mental status abnormalities resulting from medications, alcohol abuse, drug use, effects of hyponatremia, and psychiatric disease. Therefore, as clinically indicated, exclusion of other etiologies by laboratory and radiological assessment for a patient with altered mental status in HE is warranted.

Testing for MHE and CHE

Minimal hepatic encephalopathy and CHE is defined as the presence of test-dependent or clinical signs of brain dysfunction in patients with CLD who are not disoriented or display asterixis. The term “minimal” conveys that there is no clinical sign, cognitive or other, of HE. The term “covert” includes minimal and grade 1 HE. Testing strategies can be divided into two major types: psychometric and neurophysiological.^{97,98} Because the condition affects several components of cognitive functioning, which may not be impaired to the same degree, the ISHEN suggests the use of at least two tests, depending on the local population norms and availability, and preferably with one of the tests being more widely accepted so as to

serve as a comparator. Testing for MHE and CHE is important because it can prognosticate OHE development, indicate poor quality of life and reduced socioeconomic potential, and help counsel patients and caregivers about the disease. The occurrence of MHE and CHE in patients with CLD seems to be as high as 50%,⁹⁹ so, ideally, every patient at risk should be tested. However, this strategy may be costly,¹⁰⁰ and the consequences of the screening procedure are not always clear and treatment is not always recommended. An operational approach may be to test patients who have problems with their quality of life or in whom there are complaints from the patients and their relatives.¹⁰¹ Tests positive for MHE or CHE before stopping HE drug therapy will identify patients at risk for recurrent HE.¹⁰² Furthermore, none of the available tests are specific for the condition,¹⁰³ and it is important to test only patients who do not have confounding factors, such as neuropsychiatric disorders, psychoactive medication, or current alcohol use. Testing should be done by a trained examiner adhering to scripts that accompany the testing tools. If the test result is normal (i.e., negative for MHE or CHE), repeat testing in 6 months has been recommended.¹⁰⁴ A diagnosis of MHE or CHE does not automatically mean that the affected subject is a dangerous driver.¹⁰⁵ Medical providers are not trained to formally evaluate fitness to drive and are also not legal representatives. Therefore, providers should act in the best interests of both the patient and society while following the applicable local laws.¹⁰⁵ However, doctors cannot evade the responsibility of counseling patients with diagnosed HE on the possible dangerous consequences of their driving, and, often, the safest advice is to stop driving until the responsible driving authorities have formally cleared the patient for safe driving. In difficult cases, the doctor should consult with the authorities that have the expertise to test driving ability and the authority to revoke the license. A listing of

the most established testing strategies is given below. The test recommendation varies depending on the logistics, availability of tests, local norms, and cost.^{92,93}

1. Portosystemic encephalopathy (PSE) syndrome test. This test battery consists of five paper-pencil tests that evaluate cognitive and psychomotor processing speed and visuomotor coordination. The tests are relatively easy to administer and have good external validity.¹⁰³ The test is often referred to as the Psychometric Hepatic Encephalopathy Score (PHES), with the latter being the sum score from all subtests of the battery. It can be obtained from Hannover Medical School (Hannover, Germany), which holds the copyright (Weissenborn.karin@mh-hannover.de). The test was developed in Germany and has been translated for use in many other countries. For illiterate patients, the figure connection test has been used as a subtest instead of the number connection test.¹⁰⁶

2. The Critical Flicker Frequency (CFF) test is a psycho physiological tool defined as the frequency at which a fused light (presented from 60 Hz downward) appears to be flickering to the observer. Studies have shown its reduction with worsening cognition and improvement after therapy. The CFF test requires several trials, intact binocular vision, absence of red-green blindness, and specialized equipment.^{107,108}

3. The Continuous Reaction Time (CRT) test. The CRT test relies on repeated registration of the motor reaction time (pressing a button) to auditory stimuli (through headphones). The most important test result is the CRT index, which measures the stability of the reaction times. The test result can differentiate between organic and metabolic brain impairment and is not influenced by the patient's age or gender, and there is no learning or tiring effect. Simple software and hardware are required.¹⁰⁹

4. The Inhibitory Control Test (ICT) is a computerized test of response inhibition and working memory¹¹⁰ and is freely downloadable at www.hecme.tv. The ICT test has

been judged to have good validity, but requires highly functional patients. The norms for the test have to be elaborated beyond the few centers that have used it.

5. The Stroop test evaluates psychomotor speed and cognitive flexibility by the interference between recognition reaction time to a colored field and a written color name. Recently, mobile application software (“apps” for a smartphone or tablet computer) based on the test has been shown to identify cognitive dysfunction in cirrhosis compared to paper-pencil tests.¹¹¹ Further studies are under way to evaluate its potential for screening for MHE and CHE.

6. The SCAN Test is a computerized test that measures speed and accuracy to perform a digit recognition memory task of increasing complexity. The SCAN Test has been shown to be of prognostic value.¹¹²

7. Electroencephalography examination can detect changes in cortical cerebral activity across the spectrum of HE without patient cooperation or risk of a learning effect.⁹⁷ However, it is nonspecific and may be influenced by accompanying metabolic disturbances, such as hyponatremia as well as drugs. Possibly, the reliability of EEG analysis can increase with quantitative analysis. This specifically should include the background frequency with mean dominant frequency or spectral band analysis. Also, in most situations, EEG requires an institutional setup and neurological expertise in evaluation, and the cost varies among hospitals.

Although the above-described tests have been used to test for MHE and CHE, there is, most often, a poor correlation between them because HE is a multidimensional dysfunction.¹¹³ Learning effect is often observed with psychometric tests and it is unclear whether current HE therapy plays a role in the test performance. Therefore, interpretation of these tests and consideration of the results for further management need an understanding of the patient’s history, current therapy, and

effect on the patient's daily activities, if signs of HE are found. For multicenter studies, the diagnosis of MHE or CHE by consensus should utilize at least two of the current validated testing strategies: paper-pencil (PHES) and one of the following: computerized (CRT, ICT, SCAN, or Stroop) or neurophysiological (CFF or EEG).⁹³ In the clinical routine or single-center studies, investigators may use tests for assessing the severity of HE with which they are familiar, provided that normative reference data are available and the tests have been validated for use in this patient population.⁹³

Laboratory Testing

High blood-ammonia levels alone do not add any diagnostic, staging, or prognostic value in HE patients with CLD.¹¹⁴ However, in case an ammonia level is checked in a patient with OHE and it is normal, the diagnosis of HE is in question. For ammonia-lowering drugs, repeated measurements of ammonia may be helpful to test the efficacy. There may be logistic challenges to accurately measure blood ammonia, which should be taken into consideration. Ammonia is reported either in venous, arterial blood, or plasma ammonia, so the relevant normal should be used. Multiple methods are available, but measurements should only be employed when laboratory standards allow for reliable analyses.

Brain Scans

Computed tomography (CT) or magnetic resonance (MRI) or other image modality scans do not contribute diagnostic or grading information. However, the risk of intracerebral hemorrhage is at least 5-fold increased in this patient group,¹¹⁵ and the symptoms may be indistinguishable, so a brain scan is usually part of the diagnostic workup of first-time HE and on clinical suspicion of other pathology.

TREATMENT

General Principles

At this time, only OHE is routinely treated. Minimal hepatic encephalopathy and CHE, as its title implies, is not obvious on routine clinical examination and is predominantly diagnosed by techniques outlined in the previous section. Despite its subtle nature, MHE and CHE can have a significant effect on a patient's daily living. Special circumstances can prevail where there may be an indication to treat such a patient (e.g., impairment in driving skills, work performance, quality of life, or cognitive complaints). Liver transplantation is mentioned under the treatment recommendations. Comments on Management Strategy Patients with higher grades of HE who are at risk or unable to protect their airway need more intensive monitoring and are ideally managed in an intensive care setting. Alternative causes of encephalopathy are not infrequent in patients with advanced cirrhosis. Technically, if other causes of encephalopathy are present, then the episode of encephalopathy may not be termed HE. In the clinical setting, what transpires is treatment of both HE and non-HE. Controlling precipitating factors in the management of OHE is of paramount importance, because nearly 90% of patients can be treated with just correction of the precipitating factor.¹¹⁶ Careful attention to this issue is still the cornerstone of HE management.

Therapy for Episodes of OHE

In addition to the other elements of the fourpronged approach to treatment of HE, specific drug treatment is part of the management. Most drugs have not been tested by rigorous randomized, controlled studies and are utilized based on circumstantial observations. These agents include nonabsorbable disaccharides, such as lactulose, and antibiotics, such as rifaximin. Other therapies, such as oral branched-

chain amino acids (BCAAs), intravenous (IV) L-ornithine Laspartate (LOLA), probiotics, and other antibiotics, have also been used. In the hospital, a nasogastric tube can be used to administer oral therapies in patients who are unable to swallow or have an aspiration risk. Nonabsorbable Disaccharides. Lactulose is generally used as initial treatment for OHE. A large metaanalysis of trial data did not completely support lactulose as a therapeutic agent for treatment of OHE, but for technical reasons, it did not include the largest trials, and these agents continue to be used widely.¹¹⁷ Lack of effect of lactulose should prompt a clinical search for unrecognized precipitating factors and competing causes for the brain impairment. Though it is assumed that the prebiotic effects (the drug being a nondigestible substance that promotes the growth of beneficial microorganisms in the intestines) and acidifying nature of lactulose have an additional benefit beyond the laxative effect, culture-independent studies have not borne those out.^{102,118} In addition, most recent trials on lactulose have been open label in nature. Cost considerations alone add to the argument in support of lactulose.¹¹⁹ In some centers, lactitol is preferred to lactulose, based on small meta-analyses of even smaller trials.^{120,121} In populations with a high prevalence of lactose intolerance, the use of lactose has been suggested.¹²² However, the only trial to show that stool acidifying enemas (lactose and lactulose) were superior to tap water enemas was underpowered.¹²³ The use of polyethylene glycol preparation¹²⁴ needs further validation. The dosing of lactulose should be initiated¹²⁵ when the three first elements of the four-pronged approach are completed, with 25mL of lactulose syrup every 1-2 hours until at least two soft or loose bowel movements per day are produced. Subsequently, the dosing is titrated to maintain two to three bowel movements per day. This dose reduction should be implemented. It is a misconception that lack of effect of smaller amounts of lactulose is remedied by much

larger doses. There is a danger for overuse of lactulose leading to complications, such as aspiration, dehydration, hypernatremia, and severe perianal skin irritation, and overuse can even precipitate HE.¹²⁶

Rifaximin

Rifaximin has been used for the therapy of HE in a number of trials¹²⁷ comparing it with placebo, other antibiotics, nonabsorbable disaccharides, and in dose-ranging studies. These trials showed effect of rifaximin that was equivalent or superior to the compared agents with good tolerability. Long-term cyclical therapy over 3-6 months with rifaximin for patients with OHE has also been studied in three trials (two compared to nonabsorbable disaccharides and one against neomycin) showing equivalence in cognitive improvement and ammonia lowering. A multinational study¹²⁸ with patients having two earlier OHE bouts to maintain remission showed the superiority of rifaximin versus placebo (in the background of 91% lactulose use). No solid data support the use of rifaximin alone. Other Therapies. Many drugs have been used for treatment of HE, but data to support their use are limited, preliminary, or lacking. However, most of these drugs can safely be used despite their limited proven efficacy.

BCAAs.

An updated meta-analysis of eight randomized, controlled trials (RCTs) indicated that oral BCAA-enriched formulations improve the manifestations of episodic HE whether OHE or MHE.¹²⁹ There is no effect of IV BCAA on the episodic bout of HE.

Metabolic Ammonia Scavengers.

These agents, through their metabolism, act as urea surrogates excreted in urine. Such drugs have been used for treatment of inborn errors of the urea cycle for

many years. Different forms are available and currently present as promising investigational agents. Ornithine phenylacetate has been studied for HE, but further clinical reports are awaited.¹³⁰ Glyceryl phenylbutyrate (GPB) was tested in a recent RCT¹³¹ on patients who had experienced two or more episodes of HE in the last 6 months and who were maintained on standard therapy (lactulose 6 rifaximin). The GPB arm experienced fewer episodes of HE and hospitalizations as well as longer time to first event. More clinical studies on the same principle are under way and, if confirmed, may lead to clinical recommendations. L-ornithine L-aspartate (LOLA). An RCT on patients with persistent HE demonstrated improvement by IV LOLA in psychometric testing and postprandial venous ammonia levels.¹³² Oral supplementation with LOLA is ineffective.

Probiotics.

A recent, open-label study of either lactulose, probiotics, or no therapy in patients with cirrhosis who recovered from HE found fewer episodes of HE in the lactulose or probiotic arms, compared to placebo, but were not different between either interventions. There was no difference in rates of readmission in any of the arms of the study.¹³³

Glutaminase Inhibitors.

Portosystemic shunting up-regulates the intestinal glutaminase gene so that intestinal glutaminase inhibitors may be useful by reducing the amounts of ammonia produced by the gut. Neomycin. This antibiotic still has its advocates and was widely used in the past for HE treatment; it is a known glutaminase inhibitor.¹³⁴

Metronidazole.

As short-term therapy,¹³⁵ metronidazole also has advocates for its use. However, longterm ototoxicity, nephrotoxicity, and neurotoxicity make these agents unattractive for continuous long-term use.

Flumazenil.

This drug is not frequently used. It transiently improves mental status in OHE without improvement on recovery or survival. The effect may be of importance in marginal situations to avoid assisted ventilation. Likewise, the effect may be helpful in difficult differential diagnostic situations by confirming reversibility (e.g., when standard therapy unexpectedly fails or when benzodiazepine toxicity is suspected).

Laxatives.

Simple laxatives alone do not have the prebiotic properties of disaccharides, and no publications have been forthcoming on this issue.

Albumin.

A recent RCT on OHE patients on rifaximin given daily IV albumin or saline showed no effect on resolution of HE, but was related to better postdischarge survival.¹³⁶ Prevention of Overt Hepatic Encephalopathy After an Episode of OHE. There are no randomized, placebo-controlled trials of lactulose for maintenance of remission from OHE. However, it is still widely recommended and practiced. A single-center, open-label RCT of lactulose demonstrated less recurrence of HE in patients with cirrhosis. A recent RCT supports lactulose as prevention of HE subsequent to upper gastrointestinal (GI) bleeding.¹³⁷ Rifaximin added to lactulose is

the best-documented agent to maintain remission in patients who have already experienced one or more bouts of OHE while on lactulose treatment after their initial episode of OHE.¹²⁸

Hepatic Encephalopathy After TIPS.

Once TIPS was popularized to treat complications of PH, its tendency to cause the appearance of HE, or less commonly, intractable persistent HE, was noted. Faced with severe HE as a complication of a TIPS procedure, physicians had a major dilemma. Initially, it was routine to use standard HE treatment to prevent post-TIPS HE. However, one study illustrated that neither rifaximin nor lactulose prevented post-TIPS HE any better than placebo.¹³⁸ Careful case selection has reduced the incidence of severe HE post-TIPS. If it occurs, shunt diameter reduction can reverse HE.¹³⁹ However, the original cause for placing TIPS may reappear. Another important issue with TIPS relates to the desired portal pressure (PP) attained after placement of stents. Too low a pressure because of large stent diameter can lead to intractable HE, as noted above. There is a lack of consensus on whether to aim to reduce PP by 50% or below 12 mmHg. The latter is associated with more bouts of encephalopathy.¹⁴⁰ It is widely used to treat post-TIPS recurrent HE as with other cases of recurrent HE, including the cases that cannot be managed by reduction of shunt diameter.

Hepatic Encephalopathy Secondary to Portosystemic Shunts (PSSs).

Recurrent bouts of overt HE in patients with preserved liver function consideration should lead to a search for large spontaneous PSSs. Certain types of shunts, such as splenorenal shunts, can be successfully embolized with rapid clearance of overt HE in

a fraction of patients in a good liver function status, despite the risk for subsequent VB.¹⁴¹

Discontinuation of Prophylactic Therapy. There is a nearly uniform policy to continue treatment indefinitely after it has successfully reversed a bout of OHE. The concept may be that once the thresholds for OHE is reached, then patients are at high risk for recurrent episodes. This risk appears to worsen as liver function deteriorates. However, what often occurs are recurrent bouts of OHE from a well-known list of precipitating factors. If a recurrent precipitating factor can be controlled, such as recurrent infections or variceal hemorrhages, then HE recurrence may not be a risk and HE therapy can be discontinued. Even more influential on the risk for further bouts of OHE is overall liver function and body habitus. If patients recover a significant amount of liver function and muscle mass from the time they had bouts of OHE, they may well be able to stop standard HE therapy. There are very little data on this issue, but tests positive for MHE or CHE before stopping HE drug therapy will predict patients at risk for recurrent HE.

Treatment of Minimal HE and Covert HE

Although it is not standard to offer therapy for MHE and CHE, studies have been performed using several modes of therapy. The majority of studies have been for less than 6 months and do not reflect the overall course of the condition. Trials span the gamut from small open-label trials to larger, randomized, controlled studies using treatments varying from probiotics, lactulose, and rifaximin. Most studies have shown an improvement in the underlying cognitive status, but the mode of diagnosis has varied considerably among studies. A minority of studies used clinically relevant

endpoints. It was shown, in an open-label study,¹⁴² that lactulose can prevent development of the first episode of OHE, but the study needs to be replicated in a larger study in a blinded fashion before firm recommendations can be made. Studies using lactulose and rifaximin have shown improvement in quality of life,¹⁴³ and also in driving simulator performance.¹⁴⁴ Probiotics have also been used, but the open-label nature, varying amounts and types of organisms, and different outcomes make them difficult to recommend as therapeutic options at this time.¹⁴⁵⁻¹⁴⁸ Because of the multiple methods used to define MHE and CHE, varying endpoints, short-term treatment trials, and differing agents used in trials to date, routine treatment for MHE is not recommended at this stage. Exceptions could be made on a case-by-case basis using treatments that are approved for OHE, particularly for patients with CHE and West Haven Grade I HE.

Nutritional Recommendations:¹⁴⁹⁻¹⁵³

1. Daily energy intakes should be 35-40 kcal/kg ideal body weight (GRADE I, A, 1).
2. Daily protein intake should be 1.2-1.5 g/kg/ day (GRADE I, A, 1).
3. Small meals or liquid nutritional supplements evenly distributed throughout the day and a latenight snack should be offered (GRADE I, A, 1).
4. Oral BCAA supplementation may allow recommended nitrogen intake to be achieved and maintained in patients intolerant of dietary protein (GRADE II-2, B, 2).

Follow-up

After a hospital admission for HE, the following issues should be addressed.

Discharge From Hospital

1. The medical team should confirm the neurological status before discharge and judge to what extent the patient's neurological deficits could be attributable to HE, or

to other neurological comorbidities, for appropriate discharge planning. They should inform caregivers that the neurological status may change once the acute illness has settled and that requirement for medication could change.

2. Precipitating and risk factors for development of HE should be recognized. Future clinical management should be planned according to (1) potential for improvement of liver function (e.g., acute alcoholic hepatitis, autoimmune hepatitis, and hepatitis B), (2) presence of large portosystemic shunts (which may be suitable for occlusion), and (3) characteristics of precipitating factors (e.g., prevention of infection, avoidance of recurrent GI bleeding, diuretics, or constipation).

3. Out-patient postdischarge consultations should be planned to adjust treatment and prevent the reappearance of precipitating factors. Close liaison should be made with the patient's family, the general practitioner, and other caregivers in the primary health service, so that all parties involved understand how to manage HE in the specific patient and prevent repeated hospitalizations.

Preventive Care After Discharge

1. *Education of patients and relatives should include* (1) effects of medication (lactulose, rifaximin, and so on) and the potential side effects (e.g., diarrhea), (2) importance of adherence, (3) early signs of recurring HE, and (4) actions to be taken if recurrence (e.g., anticonstipation measures for mild recurrence and referral to general practitioner or hospital if HE with fever).

2. *Prevention of recurrence:* the underlying liver pathology may improve with time, nutrition, or specific measures, but usually patients who have developed OHE have advanced liver failure without much hope for functional improvements and are often potential LT candidates. Managing the complications of cirrhosis (e.g., spontaneous

bacterial peritonitis and GI bleeding) should be instituted according to available guidelines. Pharmacological secondary prevention is mentioned above.

3. Monitoring neurological manifestations is necessary in patients with persisting HE to adjust treatment and in patients with previous HE to investigate the presence and degree of MHE or CHE or signs of recurring HE. The cognitive assessment depends on the available normative data and local resources. The motor assessment should include evaluation of gait and walking and consider the risk of falls.

4. The socioeconomic implications of persisting HE or MHE or CHE may be very profound. They include a decline in work performance, impairment in quality of life, and increase in the risk of accidents. These patients often require economic support and extensive care from the public social support system and may include their relatives. All these issues should be incorporated into the follow-up plan.

5. Treatment endpoints depend on the monitoring used and the specialist clinic, but at least they have to cover two aspects: (1) cognitive performance (improvement in one accepted test as a minimum) and (2) daily life autonomy (basic and operational abilities).

6. Nutritional aspects: weight loss with sarcopenia may worsen HE, and, accordingly, the nutritional priority is to provide enough protein and energy to favor a positive nitrogen balance and increase in muscle mass, as recommended above.

7. Portosystemic shunt: occlusion of a dominant shunt may improve HE in patients with recurring HE and good liver function.¹⁴¹ Because the current experience is limited, the risks and benefits must be weighed before employing this strategy.

METHODOLOGY

3.1 Study design:

This study aimed to find out Precipitating factors for Hepatic Encephalopathy in Cirrhosis of Liver at KLES DR PRABHAKAR KORE HOSPITAL. A cross sectional study design was used to conduct the study.

3.2 Study site and area:

Data was collected from the patients presenting to Department of Internal medicine at KLES Dr Prabhakar Kore Hospital & MRC, Belgaum fulfilling inclusion criteria.

Duration of study: One year

Period of study: January 2015 to Dec 2015

3.3 Method of the Collection of the Data

Patients admitted with hepatic encephalopathy with cirrhosis of liver will be subjected to detailed history, examination and processed through necessary investigations with informed consent

Sample size: 84

sample size calculation $4pq/d^2$ (prevalence of HE in CL at any given time is 30 to 45 %^{1,2}) absolute error 10%

3.5 Sample selection criteria:

3.5.1 Inclusion criteria:

All cases of cirrhosis of liver with hepatic encephelopathy

3.5.2 Exclusion criteria:

EXCLUSION CRITERIA:

- 1) Age < 18 years
- 2) Metabolic disorders with encephelopathies
- 3) Encephalitis
- 4) Degenerative neurological diseases
- 5) Cerebrovascular accident
- 6) Intra-cerebral space occupying lesions

3.6 Procedure of data collection:

- 1) All the patients fulfilling the inclusion criteria and willing to participate, will be included in the study.
- 2) Informed consent will be obtained. If in any case patient is unconscious or disoriented consent will be obtained from authorised legal representative.
- 3) Further they will be subjected to a detailed history, clinical examination, investigations and imaging as in predesigned proforma.
- 4) Data will be analysed and tabulated for etiological profile of the patients.

At very beginning it was clarified that the participant had the right to refuse to answer of any question during completing questionnaire. They could withdraw from the study at any time. It was also clarified to all participants about the aim of the study. Participants were ensured that any personal information would not be published anywhere. After taking consent form the participants, they are subjected to a detailed history, clinical examination, laboratory investigations and imaging where ever required.

As this is a study of precipitating factors for HE in CL patients are not oriented to time and person with irrelevant speech in most of the patients where patients attender becomes the informant . All the data were collected by the researcher own to avoid the errors.

3.8 Field test:

Prior to collect data a field test was performed with 10 participants in the KLES Dr Prabhakar Kore Hospital. To make a feasible questionnaire was translated into kannada, Marathi and hindi. This test was performed to determine any difficulties that are exist in the questionnaires as well as the procedure of data collection. This test also helped the researcher to check the appropriateness of wording as well as ease of understanding of the questions and diagnosing a precipitating factor for HE.

3.9 Data analysis:

Descriptive statistics was used to analyze data. Descriptive statistics refers methods of describing a set of results in terms of their most interesting characteristics . Data were analyzed with the software named Statistical Package for the Social Science (SPSS) version 16.0. The variables were labeled in a list and established a computer based data definition record file that consist of a list of variables in order,

put the name of the variables in the variable view of SPSS and defined the types, values, decimal, label alignment and measurement level of data. The next step was cleaning new data files to check the inputted data set to ensure that all data had been accurately transcribed from the questionnaire sheet to the SPSS data view. Then the raw data was ready for analysis in SPSS. Data was analyzed by descriptive statistics and calculated as percentages and presented by using table, bar graph etc. Microsoft office Excel 2007 is used to decorating the bar graph.

3.10 Ethical consideration:

Ethical committee clearance was taken before starting the study. During the course of this study, interested subjects were given consent forms and the purpose of the research and the consent form were explained to them verbally in Kannada, Marathi or Hindi. The participants were informed that their participation would be fully voluntary and they had the right to withdraw or discontinue from the research at any time without any hesitation or risk. They were also informed that confidentiality would be maintained. Information might be published in any presentations or writing, but their personal identity such as their name and address will not be mention in the study. The participants were informed that the data was collected by written questionnaire. The supervisor also checked the consent form and questionnaire. For this study took permission during interview from every single participant with signature or thumb impression on a written consent form of the participants who were interested. The participants were informed about their role in the research process. The participants were informed about the aim of the research and procedures involved in the study. They were also informed that if they wish they were free to withdraw from the study any time. The study information only discusses with supervisor but

this would not share with any other person. These materials were disposed off after completion of the research project. The study results might not have any direct effects on them. Participants were also informed that they would not get any harmful things from the study.

3.11 Limitations

Despite best efforts with research, the present study was not completely free from all limitation and impediments. Limitations are:

- Sample size was small to generalize the study result.
- This study was done in a short period, so all factors in relation to precipitating factors for HE in CL cannot be studied
- Study was conducted only in KLE Dr PRABHAKAR KORE HOSPITAL AND MEDICAL RESEARCH CENTRE. So this study result would not be generalized for whole INDIA.
- To identify specifically that this is the only precipitating factor of HE in a given patient cannot be confirmed. This can be limitation of this study.
- Time and resources are limited have a great deal of impact on the study.

RESULTS


This study was conducted in KLES DR PRABHAKAR KORE HOSPITAL between January 2015 to December 2015.

4.1 AGE GROUP

The distribution of the subjects into the age group was as follows:

Table1: Age wise distribution

| Age groups | No of patients | % of patients |
|------------|----------------|---------------|
| <=30yrs | 4 | 4.76 |
| 31-40yrs | 20 | 23.81 |
| 41-50yrs | 27 | 32.14 |
| 51-60yrs | 21 | 25.00 |
| 61+yrs | 12 | 14.29 |
| Total | 84 | 100.00 |
| Mean age | 47.95 | |
| SD age | 11.14 | |



Graph:1 A total of 84 patients have participated. There are maximum number of patients in age group of 31-60 years 80.95% (68).


Table2: Distribution of patients by gender

| GENDER | NUMBER OF PATIENTS | PERCENTAGE OF PATIENTS |
|--------|--------------------|------------------------|
| Male | 81 | 96.43% |
| Female | 3 | 3.57% |
| Total | 84 | 100% |

Out of 84 patients of HE 96.43%(81) patients are male patients.

Table3: Education wise distribution

| Education | No of patients | % of patients |
|-------------------|----------------|---------------|
| Illiterates | 34 | 40.48 |
| Primary | 14 | 16.67 |
| Secondary | 8 | 9.52 |
| Higher secondary | 7 | 8.33 |
| Degree and others | 21 | 25.00 |
| Total | 84 | 100.00 |



Graph 2 According to level of education 40.48%(34) patients were illiterates.

Table 4: Precipitating factors for hepatic encephalopathy in order of frequency

| Precipitating factors for HE | Number of patients | Percentage |
|-------------------------------------|---------------------------|-------------------|
| Infection | 35 | 41.67% |
| Upper GI bleeding | 27 | 32.14% |
| Hyponatraemia | 14 | 16.67% |
| Hepatorenal syndrome | 10 | 11.90% |
| Hyperkalemia | 9 | 10.71% |
| hypomagnesemia | 7 | 8.33% |
| constipation | 4 | 4.76% |

Infection 41.67%(35) is the most common precipitating factor for HE.

Electrolyte imbalance seen in 34.52%(29) patients.

32.14%(27) patients had upper GI bleeding.

Hepatorenal syndrome is seen in 11.90%(10) patients.

Constipation is seen in 4.76%(4) patients.

Table 5: Spontaneous bacterial peritonitis as a precipitating factor

| Spontaneous bacterial peritonitis | No of patients | % of patients |
|-----------------------------------|----------------|---------------|
| Absent | 66 | 78.57 |
| Present | 18 | 21.43 |
| Total | 84 | 100.00 |




Figure 3 In this study ,spontaneous bacterial peritonitis is present in 21.43%(18) patients of HE .

Table :6 HE caused by other infections (cellulitis, pneumonia, acute gastroenteritis etc)

| Other Infection | No of patients | % of patients |
|-----------------|----------------|---------------|
| Absent | 67 | 79.76 |
| Present | 17 | 20.24 |
| Total | 84 | 100.00 |




Figure 4 In this study other infections 20.24%(17) is cause for HE.

Table:7 Upper GI bleeding as a precipitating factor

| Upper GI bleeding | No of patients | % of patients |
|-------------------|----------------|---------------|
| Absent | 57 | 67.86 |
| Present | 27 | 32.14 |
| Total | 84 | 100.00 |




Figure 5 In this study upper GI bleed is present in 32.14%(27) of patients of HE.

Table: 8 Hyponatraemia as a precipitating factor

| Hyponatraemia | No of patients | % of patients |
|---------------|----------------|---------------|
| Absent | 70 | 83.33 |
| Present | 14 | 16.67 |
| Total | 84 | 100.00 |




Figure 6: In 84 patients of HE hyponatremia was present in 16.67%(14) patients

Table:9 Hepatorenal syndrome as a precipitating factor

| Hepatorenal syndrome | No of patients | % of patients |
|----------------------|----------------|---------------|
| Absent | 74 | 88.10 |
| Present | 10 | 11.90 |
| Total | 84 | 100.00 |




Figure 7 In 84 patients of hepatic encephalopathy,11.90%(10) patients have hepatorenal syndrome.

Table:10 Hyperkalaemia as a precipitating factor

| Hyperkalaemia | No of patients | % of patients |
|---------------|----------------|---------------|
| Absent | 75 | 89.29 |
| Present | 9 | 10.71 |
| Total | 84 | 100.00 |




Figure 8 In this study hyperkalemia was seen in 10.71%(9) of patients with HE.

Table:11 Hypomagnesemia as a precipitating factor

| Hypomagnesemia | No of patients | % of patients |
|----------------|----------------|---------------|
| Absent | 77 | 91.67 |
| Present | 7 | 8.33 |
| Total | 84 | 100.00 |




Figure 9 In this study , hypomagnaesemia is seen in 8.33%(7) patients.

Table:12 Constipation as a precipitating factor

| Constipation | No of patients | % of patients |
|--------------|----------------|---------------|
| Absent | 80 | 95.24 |
| Present | 4 | 4.76 |
| Total | 84 | 100.00 |




Figure 10 In this study 4.76%(4) of patients had HE secondary to constipation.

Table:13 HE grades wise distribution

| HE grades | No of patients | % of patients |
|-----------|----------------|---------------|
| Grade I | 2 | 2.38 |
| Grade II | 49 | 58.33 |
| Grade III | 29 | 34.52 |
| Grade IV | 4 | 4.76 |
| Total | 84 | 100.00 |




Figure 11 Among the participants (N=84) about 58.33% of patients have grade II hepatic encephalopathy, 34.52% have grade III HE, 4.76%(4) have grade IVHE and 2.38%(2) have grade I HE.

Table:14 Association between single and multi precipitating factors with HE grade

| HE grade | Single precipitating factor | % | Multiple precipitating factors | % | Total | |
|-----------|-----------------------------|-------|--------------------------------|-------|-------|--------|
| Grade I | 1 | 50.00 | 1 | 50.00 | 2 | 2.38 |
| Grade II | 41 | 83.67 | 8 | 16.33 | 49 | 58.33 |
| Grade III | 19 | 65.52 | 10 | 34.48 | 29 | 34.52 |
| Grade IV | 4 | 100.0 | 0 | 0.00 | 4 | 4.76 |
| Total | 65 | 77.38 | 19 | 22.62 | 84 | 100.00 |

Chi-square=4.2221 P = 0.1212




Figure 12 Grade I HE showing equal association with single and multiple precipitating factors,

Grade II HE,43 (83.67%) were having single precipitating factor.

65.5% of patients of Grade III HE had single precipitating factor.

All Grade IV, all were showing association with single precipitating factor.

There is no association between grade of HE to number of precipitating factors as

P=0.1212 .

Table: 15 Association between Infection (Spontaneous bacterial peritonitis + other infections) with HE grades

| HE grades | Infection + Spontaneous bacterial peritonitis | | | | |
|-----------|---|-------|---------|-------|-------|
| | Absent | % | Present | % | Total |
| Grade I | 1 | 50.00 | 1 | 50.00 | 2 |
| Grade II | 26 | 53.06 | 23 | 46.94 | 49 |
| Grade III | 19 | 65.52 | 10 | 34.48 | 29 |
| Grade IV | 3 | 75.00 | 1 | 25.00 | 4 |
| Total | 49 | 58.33 | 35 | 41.67 | 84 |




Figure 13 Among 2 patients of Grade I, one was having infection. Among 49 patients of Grade II ,23(46.94%) were having infection. Among 29 patients of Grade III,10(34.48%) were having infection. Among 4 patients of Grade IV , only 1 patient was having infection.

Table: 16 Upper GI bleeding to grade of HE

| GRADE OF HE | PRESENT | ABSENT |
|-------------|---------|--------|
| GRADE I | 0 | 2 |
| GRADE II | 5 | 44 |
| GRADE III | 19 | 10 |
| GRADE IV | 3 | 1 |
| TOTAL | 27 | 57 |

70.37%(19 out of 27) patients with upper GI bleeding had Grade III HE.

Table:17 Electrolyte imbalance to HE grade

| GRADE OF HE | PRESENT | ABSENT |
|-------------|---------|--------|
| GRADE I | 2 | 0 |
| GRADE II | 21 | 28 |
| GRADE III | 6 | 23 |
| GRADE IV | 0 | 4 |
| TOTAL | 29 | 55 |

75%(21 out of 28) patients presented with electrolyte imbalance had Grade II HE.

Table: 18 Child Pugh score with Grade of Hepatic encephelopathy

| Grade of HE(WHC) | Child Pugh class B | Child Pugh class C | Total |
|------------------|--------------------|--------------------|-------|
| Grade I | 2 | 0 | 2 |
| Grade II | 41 | 8 | 49 |
| Grade III | 5 | 24 | 29 |
| Grade IV | 0 | 4 | 4 |
| Total | 48(57.14%) | 36(42.86%) | 84 |

Grade of HE is directly proportional to Child Pugh Class.

Table: 19 Association between Infection (Spontaneous bacterial peritonitis + other infections) with other causes of Hepatic Encephelopathy

| Causes | Infection (SBP + other infections) | | | | | |
|----------------------|------------------------------------|--------|---------|-------|-------|---------|
| | Absent | % | Present | % | Total | % |
| Upper GI bleeding | 24 | 88.89 | 3 | 11.11 | 27 | 0.0001* |
| Hyponatraemia | 13 | 92.86 | 1 | 7.14 | 14 | 0.0040* |
| Hypomagneseemia | 6 | 85.71 | 1 | 14.29 | 7 | 0.1250 |
| Hyperkalaemia | 9 | 100.00 | 0 | 0.00 | 9 | 0.0070* |
| Hypocalcaemia | 0 | 0.00 | 0 | 0.00 | 0 | 1.0000 |
| Constipation | 4 | 100.00 | 0 | 0.00 | 4 | 0.0830 |
| Hepatorenal syndrome | 7 | 70.00 | 3 | 30.00 | 10 | 0.4250 |

P<0.05




Figure 14 :Above figure shows presence of infection as a precipitating factor along with other factors causing HE.

3 patients of upper GI bleeding had infection.

1 patient of hyponatremia had infection.

3 patients of hepatorenal syndrome had infection.

DISCUSSION

This study was conducted in KLES DR.PRABHAKAR KORE HOSPITAL AND MRC, BELGAUM. A total of 84 patients of CL with HE have participated. There are maximum number of patients in age groups of 31-60 years 80.95% (68). 81 are male and 3 patients are female. According to level of education 40.48%(34) patients were illiterates.

In this study infection (SBP + other infections) 41.66%(35) is the commonest precipitating factor for HE, followed by electrolyte imbalance 34.52(29), upper GI bleeding in 32.14%(27) of patients and constipation 4.76%(4). In this study serum calcium levels were also tested where corrected calcium level was taken into consideration but not even a single case of HE is associated with hypocalcaemia.

In our study infections (SBP + other infections) 41.66%(35) is the commonest precipitating factor. Among the infections spontaneous bacterial peritonitis 21.43%(18) is the commonest precipitating factor followed by other infections 20.41%(17) includes cellulitis of extremities and abdominal wall 9.52%(8) , 5.95%(5) cases are pneumonia, 2 are of acute gastroenteritis and other 2 are undiagnosed but presented with fever and raised leucocyte count. In study by Yahia Z Gad¹⁵⁴ only 15.61%(37 out of 237) patients had infection as a precipitating factor for HE. In a study by Bikha ram Devrajini, syed zulfiquar ali shah, Tarachand Devrajini, Dileep kumar¹⁵⁵ showed infection 67%(58 out of 87) as a most common precipitating factor for HE. In a study by Fakhar Ali, Shameem behram khan, Anam umar¹⁵⁶ infection 36.6%(55 out of 96) is second most common cause for HE which is preceded by constipation.

Electrolyte imbalance is seen in 34.52%(29) patients. In electrolyte imbalance hyponatremia 16.67%(14) is the most commonest electrolyte disturbance causing HE. Out of 14 patients 12 patients are on diuretic therapy for ascitis.

Hepatorenal syndrome was seen in 11.90%(10) patients as a cause of precipitating factor for HE. Hyperkalemia was seen in 10.71%(9) patient. 9.52%(8) patients had hyperkalemia secondary to hepatorenal syndrome.

In our study hypomagnesaemia 8.33%(7 cases) as a precipitating factor for HE. These patients had showed dramatic response within few hours after correction of serum magnesium levels.

In study by Yahia Z Gad electrolyte imbalance is seen in only 2.95%(7 cases) of patients. In a study by Bikha ram Devrajini, syed zulfiquar ali shah, Tarachand Devrajini, Dileep kumar showed electrolyte imbalance in 10.34% (9 out of 87) of patients. In a study by Fakhar Ali, Shameem behram khan, Anam umar¹⁵⁶ electrolyte imbalance was seen in 29.33%(44cases). Our study was comparable to Fakhar ali Shameem behram khan, Anam umar.¹⁵⁶

Upper GI bleeding is the third most common 32.14%(27 patients) cause for hepatic encephalopathy with most of the patients having esophageal varices than gastric varices. In a study by Bikha ram Devrajini, syed zulfiquar ali shah, Tarachand Devrajini, Dileep kumar upper GI bleeding is seen in 45%(39 out of 87) of patients. In study by Yahia Z Gad 36.7% patients showed upper GI bleeding. In a study by Fakhar Ali, Shameem behram khan, Anam umar¹⁵⁶ upper GI beeding was present in 34% of the patients. Our findings are comparable to most of the studies

In our study constipation is seen in 4.76%(4) of patients. In study by Yahia Z Gad¹⁵⁴ constipation is seen in 49%(43) of patients.

Among the participants (N=84) Grade I HE is seen in only 2.38%(2) cases, 58.33%(49) patients have grade II hepatic encephelopathy, 34.52%(29) have grade III HE, 4.76%(4) have grade IV HE. In study by Yahia Z Gad¹⁵⁴ 33.76%(26) patients had Grade III HE, and 53.24%(41) patients had Grade IV HE

Our observation in relation to HE grade to number of precipitating factors. Grade I HE showing equal association with single and multiple precipitating factors, Grade II HE,43 (83.67%) were having single precipitating factor. 65.5% of patients of Grade III HE had single precipitating factor. All Grade IV HE had single precipitating factor.

Our observation in relation to HE grade and infection shows that Among 2 patients of Grade I, 50%(1) had infection. Among 49 patients of Grade II ,23(46.94%) were having infection. Among 29 patients of Grade III,10(34.48%) were having infection. Among 4 patients of Grade IV , only 25%(1) patient was having infection. In study by Yahia Z Gad¹⁵⁴ infection is seen in 11.68%(9) patients with Grade IV HE and 5.19%(4) patients with Grade III HE.

In our study 27 patients had upper GI bleed. 19 patients (out of 27) had Grade III HE. 29 patients had electrolyte imbalance. 21 patients (out of 29) had Grade II HE.

In our study 57.14%(48) patients had Child Pugh class B and 42.86%(36) had Child Pugh class C. Correlation of child Pugh class and HE Grade showed that

child Pugh class is directly proportional to Grades of HE. In study by Yahia Z Gad¹⁵⁴ a total of 37.66%(29) patients had child Pugh class B and 62.34%(48) had class C.

CONCLUSION

Infection is the commonest risk factor for hepatic encephalopathy, followed by electrolyte imbalance, upper GI bleeding, HRS, and constipation.

In our study we observed that hypomagnesemia is a precipitating factor for HE. Role of magnesium in causing HE in patients of CL is important as correction of it shows a dramatic response in patients with hypomagnesemia. So monitoring of serum magnesium level is important in a patient with HE. As sample size of present study is small larger studies are required to confirm the role of magnesium as a precipitating factor for HE in cirrhosis of liver patients.

SUMMARY

Hepatic encephelopathy(HE) is a syndrome observed in patients with cirrhosis of liver. Hepatic encephalopathy is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, after exclusion of brain disease¹. The present study is aimed at studying precipitating factors for hepatic encephalopathy in cirrhosis of liver.

As early detection of precipitating factors might help in prevention of further episodes of hepatic encephalopathy thus decreasing morbidity and mortality.

This study was conducted in KLES DR.PRABHAKAR KORE HOSPITAL AND MRC, BELGAUM. A total of 84 patients have been studied which showed following results.

- There are maximum number of patients in between age group of 31-60 years 80.95% (68).
- Among 84 patients only 3 patients are female and remaining all are male patients.
- According to level of education 40.48%(34) patients were illiterates.
- Infection 41.67%(35) is the most common precipitating factor for HE. 32.14%(27) patients had upper gi bleeding. Electrolyte imbalance seen in 34.52 %(29) patients. Hepatorenal syndrome is seen in 11.90%(10) patients. Constipation is seen in 4.76%(4) patients.
- In this study ,spontaneous bacterial peritonitis is present in 21.43%(18) patients of HE . infections 20.24%(17) is cause for HE.
- GI bleed is present in 32.14%(27) of patients of HE.
- Electrolyte imbalance is seen in 34.52%(29) patients. In electrolyte imbalance hyponatremia 16.67%(14) is the most commonest electrolyte disturbance causing HE.

- Hepatorenal syndrome was seen in 11.90%(10) patients as a cause of precipitating factor for HE. Hyperkalemia was seen in 10.71%(9) patient. 9.52%(8) patients had hyperkalemia secondary to hepatorenal syndrome.
- In our study hypomagnesaemia 8.33%(7 cases) is seen as precipitating factor for HE. These patients had showed dramatic response within few hours after correction of serum magnesium levels.
- constipation is seen in 4.76%(4) of patients.
- Among the participants (N=84) Grade I HE is seen in only 2 cases, 58.33%(49 patients have grade II hepatic encephelopathy, 34.52%(29) have grade III HE, 4.76%(4) have grade IV HE.
- Grade I HE showing equal association with single and multiple precipitating factors, Grade II HE,43 (83.67%) were having single precipitating factor. 65.5% of patients of Grade III HE had single precipitating factor. All Grade IV, all were showing association with single precipitating factor.
- Among 2 patients of Grade I, one was having infection. Among 49 patients of Grade II ,23(46.94%) were having infection. Among 29 patients of Grade III,10(34.48%) were having infection. Among 4 patients of Grade IV , only 1 patient was having infection. In 84 patients of HE,35(41.67%) were precipitated by infection,. in which Grade II was common.
- In our study 57.14%(48) patients had Child Pugh class B and 42.86%(36) had Child Pugh class C. As grade of HE increases so does child Pugh score and child Pugh class of the patients which shows increased mortality during next 2 years in patients presenting with higher grade of HE.

In our study we observed that hypomagnesemia is a precipitating factor for HE. Role of magnesium in causing HE in patients of CL is important as correction of it shows a dramatic response in patients with hypomagnesemia. So monitoring of serum magnesium level is important in a patient with HE.

REFERENCES

1. Scherlock S, Dooley J. Hepatic encephalopathy Diseases of the Liver and Biliary System. Oxford: Blackwell Scientific; 1993. pp. 86–101.
2. Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO Jr, Mc-Clain CJ. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. *Arch Intern Med* 1980; **140**:519-21.
3. Lockwood AH. Early detection of hepatic encephalopathy. *Neurology* 1998; **6**:663-6.
4. Nadeem M, Yousaf MA, Zakaria M, Hussain T, Ali N. The value of clinical signs in diagnosis of cirrhosis. *Pak J Med Sci* 2005;21:121-4
5. Gines P, Quintero E, Arroyo V, et al. Compensated Cirrhosis: natural history and prognostic factors. *Hepatology*. 1987;7:122–28. [[PubMed](#)]
6. Hazell AS, Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanisms. *Proc Soc Exp Biol Med*. 1999;222:99–112. [[PubMed](#)]
7. Pomier LG. TIPS and hepatic encephalopathy. *Semin Liver Dis*. 1996;16:315–20. [[PubMed](#)]
8. Rink CH, Haeting J, Nilius R. Prognosis assessment in patients with liver cirrhosis. *Hepatogastroenterology*. 1990;37(II):A86, 514.
9. Butterworth R. Alterations of neurotransmitter-related gene expression in human and experimental portal systemic encephalopathy. *Metab Brain Dis*. 1998;13:337–49. [[PubMed](#)]

10. Butterworth R. Complications of cirrhosis III. Hepatic encephalopathy. *J Hepatol.* 2000;32(1):171–80. [[PubMed](#)]
11. Nencki M, Pavlov J, Zaleski J. Ueber den ammoniakgehalt des blutes under der organe und die harnstoffbildug bei den saugethieren. *Arch Exp Pathol Pharmacol.* 1896;37:26–51.
12. Shawcross DL, Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. *Metab Brain Dis.* 2005;20:169–79. [[PubMed](#)]
13. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. *Hepatology.* 1999;29:648–53. [[PubMed](#)]
14. Rakoski MO, McCammon RJ, Piette JD, Iwashyna TJ, Marrero JA, Lok AS, et al. Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. *HEPATOLOGY* 2012;55:184-191.
15. Sherlock S, Summerskill WHJ, White LP, Phear EA. Portalsystemic encephalopathy. Neurological complications of liver disease. *The Lancet* 1954;264:453-457.
16. Fazekas JE, Ticktin HE, Shea JG. Effects of L-arginine on hepatic encephalopathy. *Am J Med Sci* 1957;234:462-467.
17. Kaplan PW, Rossetti AO. EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. *J Clin Neurophysiol* 2011;28:233-251.
18. Conn HO. Hepatic encephalopathy. In: Schiff L, Schiff ER, eds. *Diseases of the Liver.* 7th ed. Philadelphia, PA: Lippicott; 1993:1036-1060.

19. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. *Dig Dis Sci* 1986;31:468-475.
20. Ding A, Lee A, Callender M, Loughrey M, Quah SP, Dinsmore WW. Hepatic encephalopathy as an unusual late complication of transjugular intrahepatic portosystemic shunt insertion for non-cirrhotic portal hypertension caused by nodular regenerative hyperplasia in an HIVpositive patient on highly active antiretroviral therapy. *Int J STD AIDS* 2010;21:71-72.
21. Ito T, Ikeda N, Watanabe A, Sue K, Kakio T, Mimura H, et al. Obliteration of portal systemic shunts as therapy for hepatic encephalopathy in patients with non-cirrhotic portal hypertension. *Gastroenterol Jpn* 1992;27:759-764.
22. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *HEPATOLOGY* 2002;35:716-721.
23. Cordoba J. New assessment of hepatic encephalopathy. *J Hepatol* 2011;54:1030-1040.
24. Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. *Gastroenterology* 1978;75:462-469.
25. Del Piccolo F, Sacerdoti D, Amodio P, Bombonato G, Bolognesi M, Mapelli D, et al. Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypoperfusion. *Metab Brain Dis* 2002;17:347-358.

26. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. *Gastroenterology* 2010;138:2332-2340.
27. Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. *Clin Gastroenterol Hepatol* 2011;9: 181-183.
28. Saunders JB, Walters JRF, Davies P, Paton A. A 20-year prospective study of cirrhosis. *BMJ* 1981;282:263-266.
29. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. *Am J Gastroenterol* 2001;96:2718-2723.
30. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. The clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. *HEPATOLOGY* 2010;51:1675-1682.
31. Coltorti M, Del Vecchio-Blanco C, Caporaso N, Gallo C, Castellano L. Liver cirrhosis in Italy. A multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group. *Ital J Gastroenterol* 1991;23:42-48.
32. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. *HEPATOLOGY* 1999;30:612-622.
33. Nolte W, Wiltfang J, Schindler C, M nke H, Unterberg K, Zumhasch U, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic

- portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. *HEPATOLOGY* 1998;28:1215-1225.
34. Amodio P, Del Piccolo F, Pettenu E, Mapelli D, Angeli P, Iemmolo R, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. *J Hepatol* 2001;35:37-45.
35. Groeneweg M, Moerland W, Quero JC, Krabbe PF, Schalm SW. Screening of subclinical hepatic encephalopathy. *J Hepatol* 2000;32:748-753.
36. Saxena N, Bhatia M, Joshi YK, Garg PK, Tandon RK. Auditory P300 event related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study. *J Gastroenterol Hepatol* 2001;16:322-327.
37. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. *Metab Brain Dis* 2001;16:37-41.
38. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. *J Hepatol* 2007; 47:67-73.
39. Bajaj JS. Management options for minimal hepatic encephalopathy. *Expert Rev Gastroenterol Hepatol* 2008;2:785-790.
40. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. *Gastroenterology* 2009;137:885-891, 891.e1.
41. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. *HEPATOLOGY* 2007;45:549-559.

42. Amodio P, Pellegrini A, Ubiali E, Mathy I, Piccolo FD, Orsato R, et al. The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. *Clin Neurophysiol* 2006;117:2243-2251.
43. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. *HEPATOLOGY* 2010;51:306.
44. Riggio O, Angeloni S, Salvatori FM, De SA, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. *AmJ Gastroenterol* 2008;103:2738-2746.
45. Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. *J Gastroenterol Hepatol* 2011;26:943-951.
46. Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. *Clin Gastroenterol Hepatol* 2012;10:1034-1041.
47. Kim WR, Brown RS, Jr., Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. *HEPATOLOGY* 2002;36:227-242.
48. Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. *J Hepatol* 2008;49:732-738.
49. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. *Metab Brain Dis* 2004;19:253-267.

50. Montagnese S, Middleton B, Skene DJ, Morgan MY. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. *Liver Int* 2009;29:1372-1382.
51. Weissenborn K. Diagnosis of encephalopathy. *Digestion* 1998;59(Suppl 2):22-24.
52. Cadranel JF, Lebiez E, Di M, V, Bernard B, El KS, Tourbah A, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? *Am J Gastroenterol* 2001;96:515-518.
53. Delanty N, French JA, Labar DR, Pedley TA, Rowan AJ. Status epilepticus arising de novo in hospitalized patients: an analysis of 41 patients. *Seizure* 2001;10:116-119.
54. Eleftheriadis N, Fourla E, Eleftheriadis D, Karlovasitou A. Status epilepticus as a manifestation of hepatic encephalopathy. *Acta Neurol Scand* 2003;107:142-144.
55. Prabhakar S, Bhatia R. Management of agitation and convulsions in hepatic encephalopathy. *Indian J Gastroenterol* 2003;22(Suppl 2):S54-S58.
56. Weissenborn K, Bokemeyer M, Krause J, Ennen J, Ahl B. Neurological and neuropsychiatric syndromes associated with liver disease. *AIDS* 2005;19(Suppl 3):S93-S98.
57. Baccarani U, Zola E, Adani GL, Cavalletti M, Schiff S, Cagnin A, et al. Reversal of hepatic myelopathy after liver transplantation: fifteen plus one. *Liver Transpl* 2010;16: 1336-1337.
58. Tryc AB, Goldbecker A, Berding G, R mke S, Afshar K, Shahrezaei GH, et al. Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments. *J Hepatol* 2013;58:698-705.
59. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, et al.; CANONIC Study Investigators of the EASL-CLIF Consortium.

- Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). *J Hepatol* 2014;60:275-281.
60. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* 2002;35:716–721
61. Shawcross DL, Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. *Metab Brain Dis* 2005;20:169–179
62. Romero-Gomez M. Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. *Metab Brain Dis* 2005;20:319–325
63. Romero-Gomez M, Ramos-Guerrero R, Grande L, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. *J Hepatol* 2004;41:49–54
64. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. *Hepatology* 2006;44:788–794
65. Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. *Hepatology* 2002;36:1163–1171
66. Olde Damink SW, Jalan R, Deutz NE, et al. Isoleucine infusion during “simulated” upper gastrointestinal bleeding improves liver and muscle protein synthesis in cirrhotic patients. *Hepatology* 2007;45:560–568
67. Co´rdoba J, Lo´pez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. *J Hepatol* 2004;41:38–43

68. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy source in liver cirrhosis. *Biochem Biophys Res Commun* 2004;313:405–409
69. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind randomized trial. *Gastroenterology* 2003;124:1792–1801
70. Olde Damink SWM, Jalan R, Deutz NE, et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. *Hepatology* 2003;37:1277–1285
71. Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. *Gut* 2003;52:1041–1045
72. Lockwood AH. Blood ammonia levels and hepatic encephalopathy. *Metab Brain Dis* 2004;19(3–4):345–349
73. Kramer L, Tribl B, Gendo A, et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. *Hepatology* 2000;31:30–34
74. Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. *J Hepatol* 2003;38:441–446
75. Ott P, Larsen FS. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. *Neurochem Int* 2004;44:185–198
76. Watanabe A. Portal-systemic encephalopathy in noncirrhotic patients: classification of clinical types, diagnosis and treatment. *J Gastroenterol Hepatol* 2000;15:969–979

77. Ortiz M, Co´rdoba J, Alonso J, et al. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. *J Hepatol* 2004;40:552–557
78. Blei AT. Infection, inflammation and hepatic encephalopathy, synergism redefined. *J Hepatol* 2004;40:327–330
79. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory responses syndrome in acute liver failure. *Hepatology* 2000;32:734–739
80. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. *Gastroenterology* 2003;125:755–764
81. Haussinger D, Schliess F. Astrocyte swelling and protein tyrosine nitration in hepatic encephalopathy. *Neurochem Int* 2005;47;(1–2):64–70
82. Pedersen HR, Ring-Larsen H, Olsen NV, Larsen FS. Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetised with pentobarbital. *J Hepatol* 2007;47:245–252
83. Jalan R, Bernuau J. Induction of cerebral hyperemia by ammonia plus endotoxin: does hyperammonemia unlock the blood-brain barrier? *J Hepatol* 2007;47:168–171
84. Such J, Frances R, Munoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. *Hepatology* 2002;36:135–141
85. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. *Metab Brain Dis* 2002;17: 221–227

86. Ahboucha S, Layrargues GP, Mamer O, Butterworth RF. Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy. *Ann Neurol* 2005;58: 169–170
87. Norenberg MD. Oxidative and nitrosative stress in ammonia neurotoxicity. *Hepatology* 2003;37:245–248
88. Chatauret N, Zwingmann C, Rose C, Leibfritz D, Butterworth RF. Effects of hypothermia on brain glucose metabolism in acute liver failure: a H/C-nuclear magnetic resonance study. *Gastroenterology* 2003;125:815–824
89. Schliess F, Gorg B, Haüssinger D. Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm. *Biol Chem* 2006;387(10–11):1363–1370
90. Gorg B, Foster N, Reinehr R, et al. Benzodiazepine induced protein tyrosine nitration in rat astrocytes. *Hepatology* 2003;37:334–342
91. Haüssinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? *J Hepatol* 2000;32:1035–1038
92. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. *HEPATOLOGY* 2009;50:2014-2021.
93. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY. Review article: the design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. *Aliment Pharmacol Ther* 2011;33:739-747.

94. Montagnese S, Amodio P, Morgan MY. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. *Metab Brain Dis* 2004;19:281-312.
95. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. *Nat Rev Gastroenterol Hepatol* 2010;7:515-525.
96. Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). *DigDis Sci* 2008;53:529-538.
97. Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int* 2009;29:789-796.
98. Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int* 2009;29:629-635.
99. Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. *Metab Brain Dis* 2011;26:135-139.
100. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. *HEPATOLOGY* 2012;55:1164-1171.
101. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. *J Hepatol* 2005; 42(Suppl):S45-S53.
102. Bajaj JS, Gillevet PM, Patel NR, Ahluwalia V, Ridlon JM, Kettenmann B, et al. A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. *Metab Brain Dis* 2012;27:205-215.

103. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. *J Hepatol* 2001;34:768-773.
104. Prakash RK, Brown TA, Mullen KD. Minimal hepatic encephalopathy and driving: is the genie out of the bottle? *Am J Gastroenterol* 2011; 106:1415-1416.
105. Bajaj JS, Stein AC, Dubinsky RM. What is driving the legal interest in hepatic encephalopathy? *Clin Gastroenterol Hepatol* 2011;9:97-98.
106. Dhiman RK, Saraswat VA, Verma M, Naik SR. Figure connection test: a universal test for assessment of mental state. *J Gastroenterol Hepatol* 1995;10:14-23.
107. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. *HEPATOLOGY* 2002;35:357-366.
108. Romero-Gomez M, Cordoba J, Jover R, delOlmo JA, Ramirez M, Rey R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. *HEPATOLOGY* 2007;45:879-885.
109. Lauridsen MM, Thiele M, Kimer N, Vilstrup H. The continuous reaction times method for diagnosing, grading, and monitoring minimal/ covert hepatic encephalopathy. *Metab Brain Dis* 2013;28:231-234.
110. Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. *Gastroenterology* 2008;135:1591-1600.
111. Bajaj JS, Thacker LR, Heumann DM, Fuchs M, Sterling RK, Sanyal AJ, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. *HEPATOLOGY* 2013;58:1122-1132.

112. Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. *HEPATOLOGY* 1999;29:1662-1667.
113. Montagnese S, Biancardi A, Schiff S, Carraro P, Carla V, Mannaioni G, et al. Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis. *HEPATOLOGY* 2010;53:558-566.
114. Lockwood AH. Blood ammonia levels and hepatic encephalopathy. *Metab Brain Dis* 2004;19:345-349.
115. Grønbaek H, Johnsen SP, Jepsen P, Gislum M, Vilstrup H, Tage-Jensen U, Sørensen HT. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study. *BMC Gastroenterol* 2008;8:16
116. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. *Hepatogastroenterology* 1992;39:542-545.
117. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. *BMJ* 2004;328:1046.
118. Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, et al. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. *J Clin Gastroenterol* 1990;12:433-436.
119. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy—a decision analysis. *Aliment Pharmacol Ther* 2007;26:1147-1161.

120. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. *Dig Dis Sci* 1993;38:916-922.
121. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. *J Hepatol* 1987;4:236-244.
122. Uribe M, Berthier JM, Lewis H, Mata JM, Sierra JG, Garc_1a-Ramos G, et al. Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study. *Gastroenterology* 1981;81:101-106.
123. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a doubleblind, randomized clinical trial. *HEPATOLOGY* 1987;7:639-643.
124. Rahimi RS, Singal AG, Cuthbert JA, Rockey DG. A randomized trial of polyethylene glycol 3350-electrolyte solution (PEG) and lactulose for patients hospitalized with acute hepatic encephalopathy. *HEPATOLOGY* 2012;56(Suppl S1):915A-916A.[abstr. 1546]
125. Conn HO, Lieberthal MM. *The Hepatic Coma Syndromes and Lactulose*. Baltimore, MA: Williams and Wilkins; 1979.
126. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. *Aliment Pharmacol Ther* 2010;31:1012-1017.
127. Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. *Metab Brain Dis* 2013;28:307-312.

128. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 2010; 362:1071-1081.
129. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? *Metab Brain Dis* 2013;28:221-225.
130. Ventura-Cots M, Arranz JA, Simón-Talero M, Torrens M, Blanco A, Riudor E, et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. *J Clin Gastroenterol* 2013;47:881-887.
131. Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, et al.; HALT-HE Study Group. Randomized, doubleblind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. *HEPATOLOGY* 2014;59:1073-1083.
132. Kircheis G, Nilus R, Held C, Berndt H, Buchner M, Gortelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. *HEPATOLOGY* 1997;25:1351-1360.
133. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. *Am J Gastroenterol* 2012;107:1043-1050.
134. Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR. Neomycin reduces the intestinal production of ammonia from glutamine. *Adv Exp Med Biol* 1994;368:125-134.
135. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. *Gut* 1982;23:1-7.

136. Simon-Talero M, Garcia-Martinez R, Torrens M, Augustin S, Gomez S, Pereira G, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized doubleblind study. *J Hepatol* 2013;59:1184-1192.
137. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. *J Gastroenterol Hepatol* 2011;26:996-1003.
138. Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. *J Hepatol* 2005;42:674-679.
139. Fanelli F, Salvatori FM, Rabuffi P, Riggio O, Lucatelli P, et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. *AJR Am J Roentgenol* 2009;193:1696- 1702.
140. Chung HH, Razavi MK, Sze DY, Frisoli JK, Kee ST, Dake MD, et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications? *J Gastroenterol Hepatol* 2008;23:95-101.
141. Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, et al.; on behalf of the EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multi-center survey on safety and efficacy. *HEPATOLOGY* 2013;57:2448-2457.

142. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. *J Gastroenterol Hepatol* 2012;27:1329-1335.
143. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). *Am J Gastroenterol* 2011;106:307-316.
144. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. *Gastroenterology* 2011;140:478-487.
145. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. *Am J Gastroenterol* 2008;103:1707-1715.
146. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. *Eur J Gastroenterol Hepatol* 2011;23:725-732.
147. Saji S, Kumar S, Thomas V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. *Trop Gastroenterol* 2011;32:128-132.
148. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. *Aliment Pharmacol Ther* 2011;33: 662-671.

149. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kata A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: ISHEN practice guidelines. *HEPATOLOGY* 2013;58:325-336.
150. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, Sawyer MB. Muscle wasting is associated with mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2012;10:166-173.
151. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. *Liver Transpl* 2012;18: 1209-1216.
152. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. *J Gastroenterol Hepatol* 2012;27:430-441.
153. Ndraha S, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. *Acta Med Indones* 2011;43: 18-22.
154. Gad YZ precipitating factors of hepatic encephalopathy: An experience at Mansoura Specialized Medical Hospital, Egypt. *Ann Trop Med Public health* 2012;5:330-4
155. Bikha Ram Devrajani, Syed Zulfiquar Ali Shah, Tarachand Devrajani, Dileep Kumar, Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro/Hyderabad.;(JPMA59:683;2009).http://www.jpma.org.pk/full_article_text.php?article_id=1825
156. Fakhar Ali Qazi Arisar¹ , Shameem Behram Khan² , Anam Umar² ¹ Department of Medicine, Section of Gastroenterology, Aga Khan University Hospital <http://nepjol.info/index.php/AJMS> DOI: 10.3126/ajms.v6i2.11099

INFORMED CONSENT

Title of research study: PRECIPITATING FACTORS OF HEPATIC ENCEPHELOPATHY- A ONE YEAR HOSPITAL BASED CROSS SECTIONAL STUDY.

Introduction and purpose:-

Hepatic Encephelopathy is a well recognised clinical complication of cirrhosis of liver and the presence and prompt identification of well defined precipitating factors is extremely important in diagnosis and treatment of this fatal condition. About 30% of patients with cirrhosis of liver die due to hepatic coma. Early diagnosis of Hepatic Encephelopathy precipitating factors can improve the outcome.

Procedure:

If you agree to be part of the research study, you will be asked the relevant history and will be subjected to relevant clinical examination and investigations. You will also have to give blood, urine and ascetic fluid samples for the necessary investigations.

Risks and benefits:

The only risk and possible discomfort you might get is while taking blood and ascetic fluid samples for the investigations. It may cause swelling, pain, redness bruising or infection(rarely happens) at the site from where the samples are drawn.

Benefit is recognising the well defined precipitating factors of hepatic encephalopathy in cirrhosis of liver to prevent mortality.

Alternatives:

Taking part in this study is voluntary. You may choose not to take part in this study, or if you decide to take part you can later change your mind and withdraw from the study. Your decision will not change the present or future health care or other services that you receive. The study doctor or sponsor may stop your participation in this study at any time. If you choose not to take part in the study, you will receive the standard treatment for patients with your condition.

Privacy and confidentiality:

All information collected about you during the course of this study will be kept confidential to the extent permitted by law. The code numbers will identify you in this research record. WInformation from this study may be published but your identity will be confidential in any publication.

Institution/sponsors/compensation:

In case of any injury related to the study, treatment will be made available at KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Belgaum. There is no compensation or payment for such medical treatment by law.

Financial incentives for participants:

You will not be paid/offered any gifts/incentives for participating in the study.

Authorisation to publish the results:

The results of the study would be forwarded to the KLE University, Belgaum as part of requirement towards the completion of MD degree, review and publishing.

Questions/contact details

In case of the queries during study you may contact following persons.

1)Dr P Krishna Prasad,

2)Dr REKHA S PATIL

Investigator,

PROFESSOR AND HOD,

PG in General Medicine,

Dept of General Medicine,

JNMC, Belgaum.

JNMC, Belgaum.

Phone no: 08105338926

phone no: 09448371125

In case of any queries regarding your rights as participant you can contact the following person

3) Dr. Ganga Pilli, Chairman,

J.N.M.C Ethical committee for human research

Phone no: 08312471350

Extn: 1527

Consent statement by patient

I voluntarily agree to take part in this study by signing below. I may withdraw at any time. I am not giving up any of my legal rights by signing this form. My signature below indicates that I have read, or it has been read to me, this consent form, and have had all the questions answered.

Name of the participant:_____

Signature/Thumb print:_____

Name of the witness:_____

Signature/Thumb print:_____

Investigator name:_____

Signature:_____

Date:

Place:

Consent statement by relative

I voluntarily agree for the participation of my _____ to take part in this study by signing below. I may withdraw my _____ at any time. I am not giving up any of my _____ legal rights by signing this form. My signature below indicates that I have read, or it has been read to me, this consent form, and have had all the questions answered.

Name of the participant: _____

Signature/Thumb print: _____

Name of the legal representative: _____

Signature/Thumb print: _____

Investigator name: _____

Signature: _____

Date:

Place:

PROFORMA

CASE No:

NAME:

AGE/SEX:

IP NO:

ADDRESS:

OCCUPATION:

COMPLAINTS AT PRESENTATION:

PAST HISTORY:

TREATMENT HISTORY:

PHYSICAL EXAMINATION:

GENERAL CONDITION :

PALLOR: Yes/No

Icterus: Yes/No

Lymphadenopathy: Yes/No

Cyanosis: Yes/No

Clubbing: Yes/No

Edema : Yes/No

VITALS:

Temperature:

Pulse:

Respiratory rate:

Blood pressure:

Systemic examination:

R.S.:

CVS:

PA:

CNS

INVESTIGATIONS:

IMAGING:

BLOOD INVESTIGATIONS:

KEY TO MASTER CHART

HEPATIC ENCEPHALOPATHY

GRADE I : 1

GRADE II : 2

GRADE III : 3

GRADE IV : 4

M : MALE

F : FEMALE

Hyponatraemia : sodium level < 135 meq/L

Hyperkalaemia : potassium > 5.5 meq/L

Hypomagnesemia : magnesium < 1.8 meq/L

Hypocalcemia : corrected calcium < 8.8mg/dL